$elv 2019 Q1 10-Q

Concept	2019 Q1	2018 Q1
Revenue	$24.67B	$22.54B
YoY Change	9.45%	0.05%
Cost Of Revenue	$0.00	$17.05B
YoY Change	-100.0%	-2.83%
Gross Profit	$24.67B	$5.491B
YoY Change	349.21%	10.21%
Gross Profit Margin	100.0%	24.36%
Selling, General & Admin	$3.166B	$3.428B
YoY Change	-7.64%	7.42%
% of Gross Profit	12.84%	62.43%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$34.00M	$30.00M
YoY Change	13.33%	9.89%
% of Gross Profit	0.14%	0.55%
Operating Expenses	$3.166B	$3.428B
YoY Change	-7.64%	7.42%
Operating Profit	$1.940B	$1.868B
YoY Change	3.85%	17.83%
Interest Expense	$187.0M	$184.0M
YoY Change	1.63%	-21.7%
% of Operating Profit	9.64%	9.85%
Other Income/Expense, Net
YoY Change
Pretax Income	$1.945B	$1.780B
YoY Change	9.27%	17.57%
Income Tax	$394.0M	$468.0M
% Of Pretax Income	20.26%	26.29%
Net Earnings	$1.551B	$1.312B
YoY Change	18.22%	30.03%
Net Earnings / Revenue	6.29%	5.82%
Basic Earnings Per Share	$6.03	$5.13
Diluted Earnings Per Share	$5.91	$4.99
COMMON SHARES
Basic Shares Outstanding	257.1M shares	255.8M shares
Diluted Shares Outstanding	262.3M shares	262.8M shares

Concept	2019 Q1	2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$22.28B	$21.72B
YoY Change	2.55%	-12.13%
Cash & Equivalents	$4.482B	$4.631B
Short-Term Investments	$17.80B	$17.09B
Other Short-Term Assets	$2.172B	$3.552B
YoY Change	-38.86%	94.8%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$36.61B	$36.97B
YoY Change	-0.98%	-2.65%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.799B	$2.238B
YoY Change	25.09%	14.3%
Goodwill	$20.50B	$20.19B
YoY Change	1.56%	14.94%
Intangibles	$8.925B	$9.076B
YoY Change	-1.66%	14.55%
Long-Term Investments	$23.26B	$23.45B
YoY Change	-0.82%	3.49%
Other Assets	$1.453B	$832.0M
YoY Change	74.64%	29.9%
Total Long-Term Assets	$37.91B	$36.33B
YoY Change	4.37%	17.33%
TOTAL ASSETS
Total Short-Term Assets	$36.61B	$36.97B
Total Long-Term Assets	$37.91B	$36.33B
Total Assets	$74.52B	$73.30B
YoY Change	1.67%	6.32%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.951B	$5.817B
YoY Change	-32.08%	60.6%
Accrued Expenses	$694.0M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$1.095B	$1.125B
YoY Change	-2.67%	108.33%
Long-Term Debt Due	$851.0M	$650.8M
YoY Change	30.76%	-43.55%
Total Short-Term Liabilities	$22.68B	$24.76B
YoY Change	-8.38%	6.83%
LONG-TERM LIABILITIES
Long-Term Debt	$17.40B	$18.11B
YoY Change	-3.94%	17.22%
Other Long-Term Liabilities	$1.612B	$942.3M
YoY Change	71.07%	5.89%
Total Long-Term Liabilities	$19.01B	$19.05B
YoY Change	-0.23%	16.6%
TOTAL LIABILITIES
Total Short-Term Liabilities	$22.68B	$24.76B
Total Long-Term Liabilities	$19.01B	$19.05B
Total Liabilities	$44.53B	$46.29B
YoY Change	-3.81%	8.02%
SHAREHOLDERS EQUITY
Retained Earnings	$21.14B	$19.24B
YoY Change	9.85%	10.85%
Common Stock	$3.000M	$2.600M
YoY Change	15.38%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$30.00B	$27.01B
YoY Change
Total Liabilities & Shareholders Equity	$74.52B	$73.30B
YoY Change	1.67%	6.32%

Concept	2019 Q1	2018 Q1
OPERATING ACTIVITIES
Net Income	$1.551B	$1.312B
YoY Change	18.22%	30.03%
Depreciation, Depletion And Amortization	$34.00M	$30.00M
YoY Change	13.33%	9.89%
Cash From Operating Activities	$1.630B	$2.215B
YoY Change	-26.41%	-17.6%
INVESTING ACTIVITIES
Capital Expenditures	$234.0M	$218.0M
YoY Change	7.34%	70.45%
Acquisitions	$0.00	$1.346B
YoY Change	-100.0%
Other Investing Activities	-$22.00M	-$4.000M
YoY Change	450.0%	-66.1%
Cash From Investing Activities	-$652.0M	-$566.0M
YoY Change	15.19%	-53.87%
FINANCING ACTIVITIES
Cash Dividend Paid	$206.0M	$192.0M
YoY Change	7.29%	11.63%
Common Stock Issuance & Retirement, Net	$294.0M	$395.0M
YoY Change	-25.57%	679.09%
Debt Paid & Issued, Net	$63.00M	$663.0M
YoY Change	-90.5%	65.3%
Cash From Financing Activities	-$429.0M	-$627.0M
YoY Change	-31.58%	-150.8%
NET CHANGE
Cash From Operating Activities	$1.630B	$2.215B
Cash From Investing Activities	-$652.0M	-$566.0M
Cash From Financing Activities	-$429.0M	-$627.0M
Net Change In Cash	$548.0M	$1.022B
YoY Change	-46.38%	-62.08%
FREE CASH FLOW
Cash From Operating Activities	$1.630B	$2.215B
Capital Expenditures	$234.0M	$218.0M
Free Cash Flow	$1.396B	$1.997B
YoY Change	-30.1%	-22.0%

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2018Q1	antm	Accumulated Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax AccumulatedOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-2000000	USD
CY2019Q1	antm	Accumulated Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax AccumulatedOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-3000000	USD
CY2018Q1	antm	Available For Sale Securities Accumulated Other Comprehensive Income Net Deferred Tax Liability AvailableForSaleSecuritiesAccumulatedOtherComprehensiveIncomeNetDeferredTaxLiability	-5000000	USD
CY2019Q1	antm	Available For Sale Securities Accumulated Other Comprehensive Income Net Deferred Tax Liability AvailableForSaleSecuritiesAccumulatedOtherComprehensiveIncomeNetDeferredTaxLiability	-61000000	USD
CY2018Q4	antm	Available For Sale Securities Debt Maturities Amortized Cost Noncurrent AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostNoncurrent	486000000	USD
CY2019Q1	antm	Available For Sale Securities Debt Maturities Amortized Cost Noncurrent AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostNoncurrent	482000000	USD
CY2018Q1	antm	Available For Sale Securities Other Than Temporary Impairments In Accumulated Other Comprehensive Income Deferred Tax Liability Asset AvailableForSaleSecuritiesOtherThanTemporaryImpairmentsInAccumulatedOtherComprehensiveIncomeDeferredTaxLiabilityAsset	0	USD
CY2019Q1	antm	Available For Sale Securities Other Than Temporary Impairments In Accumulated Other Comprehensive Income Deferred Tax Liability Asset AvailableForSaleSecuritiesOtherThanTemporaryImpairmentsInAccumulatedOtherComprehensiveIncomeDeferredTaxLiabilityAsset	1000000	USD
CY2018Q1	antm	Cash Flow Hedging Instruments Accumulated Other Comprehensive Income Net Deferred Tax Asset CashFlowHedgingInstrumentsAccumulatedOtherComprehensiveIncomeNetDeferredTaxAsset	67000000	USD
CY2019Q1	antm	Cash Flow Hedging Instruments Accumulated Other Comprehensive Income Net Deferred Tax Asset CashFlowHedgingInstrumentsAccumulatedOtherComprehensiveIncomeNetDeferredTaxAsset	65000000	USD
CY2019Q1	antm	Percentageofrevenuessubjecttonewrevenueguidanceunder Asc606 PercentageofrevenuessubjecttonewrevenueguidanceunderASC606	0.06
CY2018Q1	antm	Potentially Dilutive Restricted Stock Units Contingent On Operating Results PotentiallyDilutiveRestrictedStockUnitsContingentOnOperatingResults	300000	shares
CY2019Q1	antm	Self Funded Receivables Net SelfFundedReceivablesNet	2491000000	USD
CY2018Q1	antm	Deferred Net Actuarial Gain Loss Postretirement Benefits DeferredNetActuarialGainLossPostretirementBenefits	-77000000	USD
CY2019Q1	antm	Deferred Net Actuarial Gain Loss Postretirement Benefits DeferredNetActuarialGainLossPostretirementBenefits	-57000000	USD
CY2018Q1	antm	Deferred Prior Service Cost Credit Postretirement Benefit Plans DeferredPriorServiceCostCreditPostretirementBenefitPlans	43000000	USD
CY2019Q1	antm	Deferred Prior Service Cost Credit Postretirement Benefit Plans DeferredPriorServiceCostCreditPostretirementBenefitPlans	31000000	USD
CY2018Q1	antm	Defined Benefit Plan Accumulated Other Comprehensive Income Adjustments Net Of Tax DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeAdjustmentsNetOfTax	-454000000	USD
CY2019Q1	antm	Defined Benefit Plan Accumulated Other Comprehensive Income Adjustments Net Of Tax DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeAdjustmentsNetOfTax	-554000000	USD
CY2018Q1	antm	Defined Benefit Plan Accumulated Other Comprehensive Income Net Deferred Tax Asset DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetDeferredTaxAsset	-159000000	USD
CY2019Q1	antm	Defined Benefit Plan Accumulated Other Comprehensive Income Net Deferred Tax Asset DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetDeferredTaxAsset	-191000000	USD
CY2018Q4	antm	Equity Securities EquitySecurities	1526000000	USD
CY2019Q1	antm	Equity Securities EquitySecurities	1244000000	USD
CY2018Q4	antm	Equity Securities Current EquitySecuritiesCurrent	1493000000	USD
CY2019Q1	antm	Equity Securities Current EquitySecuritiesCurrent	1211000000	USD
CY2018Q4	antm	Equitysecurities Longterm EquitysecuritiesLongterm	33000000	USD
CY2019Q1	antm	Equitysecurities Longterm EquitysecuritiesLongterm	33000000	USD
CY2019Q1	antm	Gross Premium Tax Rate GrossPremiumTaxRate	0.0235
CY2017Q4	antm	Increase In Stock Repurchase Program Authorization IncreaseInStockRepurchaseProgramAuthorization	5000000000	USD
CY2019Q1	antm	Lessee Operating Lease Lease Not Yet Commenced Expense LesseeOperatingLeaseLeaseNotYetCommencedExpense	104000000	USD
CY2018Q4	antm	Liability For Future Policy Benefits Current LiabilityForFuturePolicyBenefitsCurrent	75000000	USD
CY2019Q1	antm	Liability For Future Policy Benefits Current LiabilityForFuturePolicyBenefitsCurrent	78000000	USD
CY2018Q1	antm	Liability For Unpaid Claims And Claims Adjustment Expense Purchase Adjustments LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments	199000000	USD
CY2019Q1	antm	Merger Agreement Termination Fee MergerAgreementTerminationFee	1850000000	USD
CY2018Q1	antm	Netrealizedlossesgainsonfinancialinstruments Netrealizedlossesgainsonfinancialinstruments	-26000000	USD
CY2019Q1	antm	Netrealizedlossesgainsonfinancialinstruments Netrealizedlossesgainsonfinancialinstruments	78000000	USD
CY2019Q1	antm	Number Of Counties In State Of Kansas Company Does Not Serve NumberOfCountiesInStateOfKansasCompanyDoesNotServe	30	county
CY2019Q1	antm	Number Of Medical Members NumberOfMedicalMembers	41000000	medical_member
CY2018Q1	antm	Other Net Change In Unrecognized Periodic Benefit Costs For Defined Benefit Pension And Postretirement Benefit Plans Tax Benefit Expense OtherNetChangeInUnrecognizedPeriodicBenefitCostsForDefinedBenefitPensionAndPostretirementBenefitPlansTaxBenefitExpense	-3000000	USD
CY2019Q1	antm	Other Net Change In Unrecognized Periodic Benefit Costs For Defined Benefit Pension And Postretirement Benefit Plans Tax Benefit Expense OtherNetChangeInUnrecognizedPeriodicBenefitCostsForDefinedBenefitPensionAndPostretirementBenefitPlansTaxBenefitExpense	-1000000	USD
CY2018Q1	antm	Payments For Proceeds From Financing Derivatives PaymentsForProceedsFromFinancingDerivatives	-24000000	USD
CY2019Q1	antm	Payments For Proceeds From Financing Derivatives PaymentsForProceedsFromFinancingDerivatives	0	USD
CY2018Q1	antm	Paymentstoacquireequitysecurities Paymentstoacquireequitysecurities	566000000	USD
CY2019Q1	antm	Paymentstoacquireequitysecurities Paymentstoacquireequitysecurities	3691000000	USD
CY2019Q1	antm	Potentially Dilutive Restricted Stock Units Contingent On Operating Results PotentiallyDilutiveRestrictedStockUnitsContingentOnOperatingResults	200000	shares
CY2018Q1	antm	Proceedsfromsaleofequitysecurities Proceedsfromsaleofequitysecurities	1776000000	USD
CY2019Q1	antm	Proceedsfromsaleofequitysecurities Proceedsfromsaleofequitysecurities	4048000000	USD
CY2017	antm	Reclassificationofstrandedtaxeffectsresultingfromthe Tax Cutsand Jobs Act ReclassificationofstrandedtaxeffectsresultingfromtheTaxCutsandJobsAct	91000000	USD
CY2019Q1	antm	Securities Lending Transactions Initial Collateral Percentage Value SecuritiesLendingTransactionsInitialCollateralPercentageValue	1.02
CY2018	antm	Securities Lending Transactions Ratioof Fair Valueof Collateral Held To Securities On Loan SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan	1.02
CY2019Q1	antm	Securities Lending Transactions Ratioof Fair Valueof Collateral Held To Securities On Loan SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan	1.03
CY2018Q4	antm	Self Funded Receivables Net SelfFundedReceivablesNet	2278000000	USD
CY2017Q4	antm	Short Duration Contract Liability For Claims Adjustment Expense ShortDurationContractLiabilityForClaimsAdjustmentExpense	7814000000	USD
CY2018Q1	antm	Short Duration Contract Liability For Claims Adjustment Expense ShortDurationContractLiabilityForClaimsAdjustmentExpense	7453000000	USD
CY2018Q4	antm	Short Duration Contract Liability For Claims Adjustment Expense ShortDurationContractLiabilityForClaimsAdjustmentExpense	7266000000	USD
CY2019Q1	antm	Short Duration Contract Liability For Claims Adjustment Expense ShortDurationContractLiabilityForClaimsAdjustmentExpense	8028000000	USD
CY2018Q1	antm	Shortdurationcontractliabilityforunpaidclaimsandadjustmentexpense Net ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet	7419000000	USD
CY2019Q1	antm	Shortdurationcontractliabilityforunpaidclaimsandadjustmentexpense Net ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet	7994000000	USD
CY2018Q1	antm	Stock Repurchased And Retired During Period Average Price StockRepurchasedAndRetiredDuringPeriodAveragePrice	233.51
CY2019Q1	antm	Stock Repurchased And Retired During Period Average Price StockRepurchasedAndRetiredDuringPeriodAveragePrice	275.23
CY2019Q1	dei	Amendment Flag AmendmentFlag	false
CY2019Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2019Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2019Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2019Q1	dei	Document Period End Date DocumentPeriodEndDate	2019-03-31
CY2019Q1	dei	Document Type DocumentType	10-Q
CY2019Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001156039
CY2019Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	257195705	shares
CY2019Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2019Q1	dei	Entity Registrant Name EntityRegistrantName	Anthem, Inc.
CY2019Q1	dei	Trading Symbol TradingSymbol	ANTM
CY2018Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	4959000000	USD
CY2019Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3951000000	USD
CY2018Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	0	USD
CY2019Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	105000000	USD
CY2018Q4	us-gaap	Accrued Investment Income Receivable AccruedInvestmentIncomeReceivable	162000000	USD
CY2019Q1	us-gaap	Accrued Investment Income Receivable AccruedInvestmentIncomeReceivable	161000000	USD
CY2018Q1	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	14000000	USD
CY2019Q1	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	197000000	USD
CY2018Q1	us-gaap	Accumulated Other Comprehensive Income Loss Cumulative Changes In Net Gain Loss From Cash Flow Hedges Effect Net Of Tax AccumulatedOtherComprehensiveIncomeLossCumulativeChangesInNetGainLossFromCashFlowHedgesEffectNetOfTax	-255000000	USD
CY2019Q1	us-gaap	Accumulated Other Comprehensive Income Loss Cumulative Changes In Net Gain Loss From Cash Flow Hedges Effect Net Of Tax AccumulatedOtherComprehensiveIncomeLossCumulativeChangesInNetGainLossFromCashFlowHedgesEffectNetOfTax	-243000000	USD
CY2018Q1	us-gaap	Accumulated Other Comprehensive Income Loss Defined Benefit Pension And Other Postretirement Plans Net Of Tax AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax	25000000	USD
CY2019Q1	us-gaap	Accumulated Other Comprehensive Income Loss Defined Benefit Pension And Other Postretirement Plans Net Of Tax AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax	19000000	USD
CY2018Q1	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-1000000	USD
CY2019Q1	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-2000000	USD
CY2018Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-721000000	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-986000000	USD
CY2019Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-623000000	USD
CY2018Q1	us-gaap	Accumulated Other Comprehensive Income Loss Other Than Temporary Impairment Not Credit Loss Net Of Tax Availableforsale Debt Securities AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxAvailableforsaleDebtSecurities	0	USD
CY2019Q1	us-gaap	Accumulated Other Comprehensive Income Loss Other Than Temporary Impairment Not Credit Loss Net Of Tax Availableforsale Debt Securities AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxAvailableforsaleDebtSecurities	3000000	USD
CY2018Q1	us-gaap	Accumulated Other Comprehensive Income Loss Other Than Temporary Impairment Not Credit Loss Net Of Tax Debt Securities AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities	0	USD
CY2019Q1	us-gaap	Accumulated Other Comprehensive Income Loss Other Than Temporary Impairment Not Credit Loss Net Of Tax Debt Securities AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities	2000000	USD
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	9536000000	USD
CY2019Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	9482000000	USD
CY2018Q1	us-gaap	Adjustment For Amortization AdjustmentForAmortization	240000000	USD
CY2019Q1	us-gaap	Adjustment For Amortization AdjustmentForAmortization	255000000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments	-30000000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments	-52000000	USD
CY2018Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	80000000	USD
CY2019Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	87000000	USD
CY2018Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	300000	shares
CY2019Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	200000	shares
CY2018Q4	us-gaap	Assets Assets	71571000000	USD
CY2019Q1	us-gaap	Assets Assets	74523000000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	34321000000	USD
CY2019Q1	us-gaap	Assets Current AssetsCurrent	36611000000	USD
CY2018Q4	us-gaap	Assets Fair Value Disclosure Recurring AssetsFairValueDisclosureRecurring	21161000000	USD
CY2019Q1	us-gaap	Assets Fair Value Disclosure Recurring AssetsFairValueDisclosureRecurring	22708000000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	16894000000	USD
CY2019Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	17550000000	USD
CY2018Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	239000000	USD
CY2019Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	379000000	USD
CY2018Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax	19000000	USD
CY2019Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax	258000000	USD
CY2018Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	220000000	USD
CY2019Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	121000000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	16692000000	USD
CY2019Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	17795000000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	487000000	USD
CY2019Q1	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	492000000	USD
CY2018Q1	us-gaap	Available For Sale Securities Gross Realized Gains AvailableForSaleSecuritiesGrossRealizedGains	30000000	USD
CY2019Q1	us-gaap	Available For Sale Securities Gross Realized Gains AvailableForSaleSecuritiesGrossRealizedGains	18000000	USD
CY2018Q1	us-gaap	Available For Sale Securities Gross Realized Losses AvailableForSaleSecuritiesGrossRealizedLosses	36000000	USD
CY2019Q1	us-gaap	Available For Sale Securities Gross Realized Losses AvailableForSaleSecuritiesGrossRealizedLosses	17000000	USD
CY2018Q1	us-gaap	Available For Sale Securities Income Tax Expense On Change In Unrealized Holding Gain Or Loss AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss	77000000	USD
CY2019Q1	us-gaap	Available For Sale Securities Income Tax Expense On Change In Unrealized Holding Gain Or Loss AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss	-98000000	USD
CY2018Q1	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	20757000000	USD
CY2019Q1	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	22721000000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3609000000	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4631000000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3934000000	USD
CY2019Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4482000000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	1815000000	USD
CY2019Q1	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	2551000000	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1022000000	USD
CY2019Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	548000000	USD
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q1	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.75
CY2019Q1	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.8
CY2018Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.75
CY2019Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.80
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2019Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2019Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	257395577	shares
CY2019Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	257354383	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	257395577	shares
CY2019Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	257354383	shares
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	3000000	USD
CY2019Q1	us-gaap	Common Stock Value CommonStockValue	3000000	USD
CY2018Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	1103000000	USD
CY2019Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	1914000000	USD
CY2018Q4	us-gaap	Cumulative Effect Of New Accounting Principle In Period Of Adoption CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	26000000	USD
CY2018Q1	us-gaap	Cumulative Effect Of New Accounting Principle In Period Of Adoption CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	320000000	USD
CY2019Q1	us-gaap	Cumulative Effect Of New Accounting Principle In Period Of Adoption CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	26000000	USD
CY2018Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-51000000	USD
CY2019Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	55000000	USD
CY2018Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Postretirement Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits	9000000	USD
CY2019Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Postretirement Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits	7000000	USD
CY2018Q1	us-gaap	Deferred Tax Assets Unrealized Currency Losses DeferredTaxAssetsUnrealizedCurrencyLosses	1000000	USD
CY2019Q1	us-gaap	Deferred Tax Assets Unrealized Currency Losses DeferredTaxAssetsUnrealizedCurrencyLosses	1000000	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	1960000000	USD
CY2019Q1	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	2116000000	USD
CY2018Q1	us-gaap	Defined Benefit Plan Accumulated Other Comprehensive Income Net Gains Losses Before Tax DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax	-612000000	USD
CY2019Q1	us-gaap	Defined Benefit Plan Accumulated Other Comprehensive Income Net Gains Losses Before Tax DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax	-744000000	USD
CY2018Q1	us-gaap	Defined Benefit Plan Accumulated Other Comprehensive Income Net Prior Service Cost Credit Before Tax DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax	1000000	USD
CY2019Q1	us-gaap	Defined Benefit Plan Accumulated Other Comprehensive Income Net Prior Service Cost Credit Before Tax DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax	1000000	USD
CY2018Q4	us-gaap	Deposits Received For Securities Loaned At Carrying Value DepositsReceivedForSecuritiesLoanedAtCarryingValue	604000000	USD
CY2019Q1	us-gaap	Deposits Received For Securities Loaned At Carrying Value DepositsReceivedForSecuritiesLoanedAtCarryingValue	590000000	USD
CY2018Q1	us-gaap	Depreciation Depreciation	30000000	USD
CY2019Q1	us-gaap	Depreciation Depreciation	34000000	USD
CY2018Q1	us-gaap	Dividend Payable Date To Be Paid Day Month And Year DividendPayableDateToBePaidDayMonthAndYear	2018-03-23
CY2019Q1	us-gaap	Dividend Payable Date To Be Paid Day Month And Year DividendPayableDateToBePaidDayMonthAndYear	2019-03-29
CY2018Q1	us-gaap	Dividends Common Stock DividendsCommonStock	198000000	USD
CY2019Q1	us-gaap	Dividends Common Stock DividendsCommonStock	206000000	USD
CY2018Q1	us-gaap	Dividends Payable Date Declared Day Month And Year DividendsPayableDateDeclaredDayMonthAndYear	2018-01-30
CY2019Q1	us-gaap	Dividends Payable Date Declared Day Month And Year DividendsPayableDateDeclaredDayMonthAndYear	2019-01-29
CY2018Q1	us-gaap	Dividends Payable Date Of Record Day Month And Year DividendsPayableDateOfRecordDayMonthAndYear	2018-03-09
CY2019Q1	us-gaap	Dividends Payable Date Of Record Day Month And Year DividendsPayableDateOfRecordDayMonthAndYear	2019-03-18
CY2018Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	5.13
CY2019Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	6.03
CY2018Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	4.99
CY2019Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	5.91
CY2018Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	0	USD
CY2019Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-1000000	USD
CY2018Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.263
CY2019Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.203
CY2018Q1	us-gaap	Fair Value Assets Measured On Recurring Basis Change In Unrealized Gain Loss FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	-1000000	USD
CY2019Q1	us-gaap	Fair Value Assets Measured On Recurring Basis Change In Unrealized Gain Loss FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	-2000000	USD
CY2018Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1	-239000000	USD
CY2019Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1	-3000000	USD
CY2019Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Other Comprehensive Income Loss FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss	2000000	USD
CY2018Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Purchases FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases	276000000	USD
CY2019Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Purchases FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases	42000000	USD
CY2018Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Sales FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales	5000000	USD
CY2019Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Sales FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales	22000000	USD
CY2018Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements	7000000	USD
CY2019Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements	22000000	USD
CY2018Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	21000000	USD
CY2019Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	3000000	USD
CY2018Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3	1000000	USD
CY2019Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3	9000000	USD
CY2017Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	537000000	USD
CY2018Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	582000000	USD
CY2018Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	623000000	USD
CY2019Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	614000000	USD
CY2018Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-19000000	USD
CY2019Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	1000000	USD
CY2018Q4	us-gaap	Goodwill Goodwill	20504000000	USD
CY2019Q1	us-gaap	Goodwill Goodwill	20500000000	USD
CY2018Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1780000000	USD
CY2019Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1945000000	USD
CY2018Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	1780000000	USD
CY2019Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	1945000000	USD
CY2018Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	468000000	USD
CY2019Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	394000000	USD
CY2019Q1	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	83000000	USD
CY2018Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	10000000	USD
CY2019Q1	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	0	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-300000000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1029000000	USD
CY2018Q1	us-gaap	Increase Decrease In Collateral Held Under Securities Lending IncreaseDecreaseInCollateralHeldUnderSecuritiesLending	158000000	USD
CY2019Q1	us-gaap	Increase Decrease In Collateral Held Under Securities Lending IncreaseDecreaseInCollateralHeldUnderSecuritiesLending	-14000000	USD
CY2018Q1	us-gaap	Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable	537000000	USD
CY2019Q1	us-gaap	Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable	115000000	USD
CY2018Q1	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	-561000000	USD
CY2019Q1	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	791000000	USD
CY2018Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	392000000	USD
CY2019Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	125000000	USD
CY2018Q1	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	54000000	USD
CY2019Q1	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	15000000	USD
CY2018Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	147000000	USD
CY2019Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	675000000	USD
CY2018Q1	us-gaap	Increase Decrease In Outstanding Checks Financing Activities IncreaseDecreaseInOutstandingChecksFinancingActivities	-124000000	USD
CY2019Q1	us-gaap	Increase Decrease In Outstanding Checks Financing Activities IncreaseDecreaseInOutstandingChecksFinancingActivities	20000000	USD
CY2018Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-37000000	USD
CY2019Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	753000000	USD
CY2018Q1	us-gaap	Increase Decrease In Securities Lending Payable IncreaseDecreaseInSecuritiesLendingPayable	158000000	USD
CY2019Q1	us-gaap	Increase Decrease In Securities Lending Payable IncreaseDecreaseInSecuritiesLendingPayable	-14000000	USD
CY2018Q1	us-gaap	Increase Decrease In Trading Securities IncreaseDecreaseInTradingSecurities	7000000	USD
CY2019Q1	us-gaap	Increase Decrease In Trading Securities IncreaseDecreaseInTradingSecurities	21000000	USD
CY2018Q1	us-gaap	Increase Decrease In Unearned Premiums IncreaseDecreaseInUnearnedPremiums	1182000000	USD
CY2019Q1	us-gaap	Increase Decrease In Unearned Premiums IncreaseDecreaseInUnearnedPremiums	96000000	USD
CY2018Q1	us-gaap	Insurance Services Revenue InsuranceServicesRevenue	22342000000	USD
CY2019Q1	us-gaap	Insurance Services Revenue InsuranceServicesRevenue	24388000000	USD
CY2018Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	9007000000	USD
CY2019Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	8925000000	USD
CY2018Q1	us-gaap	Interest Expense InterestExpense	184000000	USD
CY2019Q1	us-gaap	Interest Expense InterestExpense	187000000	USD
CY2019Q1	us-gaap	Lease Cost LeaseCost	53000000	USD
CY2019Q1	us-gaap	Lessee Leasing Arrangements Operating Leases Renewal Term LesseeLeasingArrangementsOperatingLeasesRenewalTerm	P10Y0M0D
CY2019Q1	us-gaap	Lessee Operating Lease Lease Not Yet Commenced Description LesseeOperatingLeaseLeaseNotYetCommencedDescription	is expected to commence in 2020 when the construction is completed and we take possession of the building
CY2019Q1	us-gaap	Lessee Operating Lease Lease Not Yet Commenced Term Of Contract LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract	P12Y0M0D
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	821000000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	240000000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	134000000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	84000000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	102000000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	116000000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	145000000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	127000000	USD
CY2018Q4	us-gaap	Liabilities Liabilities	43030000000	USD
CY2019Q1	us-gaap	Liabilities Liabilities	44525000000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	71571000000	USD
CY2019Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	74523000000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	21965000000	USD
CY2019Q1	us-gaap	Liabilities Current LiabilitiesCurrent	22682000000	USD
CY2018Q4	us-gaap	Liabilities Fair Value Disclosure Recurring LiabilitiesFairValueDisclosureRecurring	17000000	USD
CY2019Q1	us-gaap	Liabilities Fair Value Disclosure Recurring LiabilitiesFairValueDisclosureRecurring	12000000	USD
CY2018Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	7454000000	USD
CY2019Q1	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	8242000000	USD
CY2018Q4	us-gaap	Liability For Future Policy Benefits LiabilityForFuturePolicyBenefits	706000000	USD
CY2019Q1	us-gaap	Liability For Future Policy Benefits LiabilityForFuturePolicyBenefits	719000000	USD
CY2018Q4	us-gaap	Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense	10119000000	USD
CY2019Q1	us-gaap	Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense	10897000000	USD
CY2018Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1	11204000000	USD
CY2019Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1	12163000000	USD
CY2018Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1	5489000000	USD
CY2019Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1	5414000000	USD
CY2018Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1	16204000000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-652000000	USD
CY2019Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1	18339000000	USD
CY2017Q4	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Net LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet	7709000000	USD
CY2018Q4	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Net LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet	7232000000	USD
CY2019Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Net LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet	7994000000	USD
CY2018Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	849000000	USD
CY2019Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	851000000	USD
CY2018Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	17217000000	USD
CY2019Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	17396000000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-627000000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-429000000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-566000000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	2215000000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1630000000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	1312000000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	1551000000	USD
CY2018Q1	us-gaap	Net Investment Income NetInvestmentIncome	229000000	USD
CY2019Q1	us-gaap	Net Investment Income NetInvestmentIncome	210000000	USD
CY2019Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	3	segment
CY2019Q1	us-gaap	Number Of States In Which Entity Operates NumberOfStatesInWhichEntityOperates	50	states
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	1868000000	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	1940000000	USD
CY2019Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	45000000	USD
CY2019Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	694000000	USD
CY2019Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	728000000	USD
CY2019Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	44000000	USD
CY2019Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	637000000	USD
CY2019Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term OperatingLeaseWeightedAverageRemainingLeaseTerm	P6Y6M0D
CY2018Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2104000000	USD
CY2019Q1	us-gaap	Other Assets Current OtherAssetsCurrent	2172000000	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	758000000	USD
CY2019Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1453000000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-256000000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	350000000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-209000000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	363000000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-209000000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	363000000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	-7000000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	-3000000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	-11000000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	-7000000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax	-3000000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax	-2000000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	63000000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	-101000000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	29000000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	3000000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax	-8000000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax	0	USD
CY2018Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-245000000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	357000000	USD
CY2018Q1	us-gaap	Other Income OtherIncome	1439000000	USD
CY2019Q1	us-gaap	Other Income OtherIncome	1545000000	USD
CY2018Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3190000000	USD
CY2019Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	4037000000	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1182000000	USD
CY2019Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1612000000	USD
CY2018Q4	us-gaap	Other Long Term Investments OtherLongTermInvestments	3726000000	USD
CY2019Q1	us-gaap	Other Long Term Investments OtherLongTermInvestments	3710000000	USD
CY2018Q4	us-gaap	Other Policyholder Funds OtherPolicyholderFunds	2590000000	USD
CY2019Q1	us-gaap	Other Policyholder Funds OtherPolicyholderFunds	2577000000	USD
CY2018Q4	us-gaap	Other Receivables OtherReceivables	2558000000	USD
CY2019Q1	us-gaap	Other Receivables OtherReceivables	2639000000	USD
CY2018Q4	us-gaap	Other Short Term Investments OtherShortTermInvestments	21000000	USD
CY2019Q1	us-gaap	Other Short Term Investments OtherShortTermInvestments	20000000	USD
CY2018Q1	us-gaap	Other Than Temporary Impairment Losses Investments Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities	8000000	USD
CY2019Q1	us-gaap	Other Than Temporary Impairment Losses Investments Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities	13000000	USD
CY2018Q1	us-gaap	Other Than Temporary Impairment Losses Investments Portion In Other Comprehensive Income Loss Before Tax Including Portion Attributable To Noncontrolling Interest Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossBeforeTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities	0	USD
CY2019Q1	us-gaap	Other Than Temporary Impairment Losses Investments Portion In Other Comprehensive Income Loss Before Tax Including Portion Attributable To Noncontrolling Interest Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossBeforeTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities	-3000000	USD
CY2018Q1	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet	8000000	USD
CY2019Q1	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet	10000000	USD
CY2018Q4	us-gaap	Payables To Broker Dealers And Clearing Organizations PayablesToBrokerDealersAndClearingOrganizations	197000000	USD
CY2019Q1	us-gaap	Payables To Broker Dealers And Clearing Organizations PayablesToBrokerDealersAndClearingOrganizations	158000000	USD
CY2018Q1	us-gaap	Payments For Losses And Loss Adjustment Expense PaymentsForLossesAndLossAdjustmentExpense	16693000000	USD
CY2019Q1	us-gaap	Payments For Losses And Loss Adjustment Expense PaymentsForLossesAndLossAdjustmentExpense	17577000000	USD
CY2018Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-4000000	USD
CY2019Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-8000000	USD
CY2018Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	395000000	USD
CY2019Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	294000000	USD
CY2018Q1	us-gaap	Payments Of Dividends PaymentsOfDividends	192000000	USD
CY2019Q1	us-gaap	Payments Of Dividends PaymentsOfDividends	206000000	USD
CY2018Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	73000000	USD
CY2019Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	78000000	USD
CY2018Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	2236000000	USD
CY2019Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	2300000000	USD
CY2018Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	1346000000	USD
CY2019Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
CY2018Q1	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	72000000	USD
CY2019Q1	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	78000000	USD
CY2018Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	218000000	USD
CY2019Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	234000000	USD
CY2018Q1	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	17046000000	USD
CY2019Q1	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	19282000000	USD
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0
CY2019Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000000	shares
CY2019Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q1	us-gaap	Premiums Earned Net PremiumsEarnedNet	20903000000	USD
CY2019Q1	us-gaap	Premiums Earned Net PremiumsEarnedNet	22843000000	USD
CY2018Q4	us-gaap	Premiums Receivable At Carrying Value PremiumsReceivableAtCarryingValue	4465000000	USD
CY2019Q1	us-gaap	Premiums Receivable At Carrying Value PremiumsReceivableAtCarryingValue	5049000000	USD
CY2018Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	836000000	USD
CY2019Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	2000000	USD
CY2018Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	363000000	USD
CY2019Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	393000000	USD
CY2018Q1	us-gaap	Proceeds From Repayments Of Commercial Paper ProceedsFromRepaymentsOfCommercialPaper	-108000000	USD
CY2019Q1	us-gaap	Proceeds From Repayments Of Commercial Paper ProceedsFromRepaymentsOfCommercialPaper	178000000	USD
CY2018Q1	us-gaap	Proceeds From Sale And Maturity Of Other Investments ProceedsFromSaleAndMaturityOfOtherInvestments	23000000	USD
CY2019Q1	us-gaap	Proceeds From Sale And Maturity Of Other Investments ProceedsFromSaleAndMaturityOfOtherInvestments	113000000	USD
CY2018Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	2227000000	USD
CY2019Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	1468000000	USD
CY2018Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	1864000000	USD
CY2019Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	1075000000	USD
CY2018Q1	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	1505000000	USD
CY2019Q1	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	2710000000	USD
CY2018Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	60000000	USD
CY2019Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	76000000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2735000000	USD
CY2019Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2799000000	USD
CY2017Q4	us-gaap	Reinsurance Recoverable For Unpaid Claims And Claims Adjustments ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments	105000000	USD
CY2018Q1	us-gaap	Reinsurance Recoverable For Unpaid Claims And Claims Adjustments ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments	34000000	USD
CY2018Q4	us-gaap	Reinsurance Recoverable For Unpaid Claims And Claims Adjustments ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments	34000000	USD
CY2019Q1	us-gaap	Reinsurance Recoverable For Unpaid Claims And Claims Adjustments ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments	34000000	USD
CY2018Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	663000000	USD
CY2019Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	63000000	USD
CY2018Q1	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	1655000000	USD
CY2019Q1	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	2760000000	USD
CY2018Q4	us-gaap	Restricted Cash And Investments Current RestrictedCashAndInvestmentsCurrent	222000000	USD
CY2019Q1	us-gaap	Restricted Cash And Investments Current RestrictedCashAndInvestmentsCurrent	262000000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	19988000000	USD
CY2019Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	21136000000	USD
CY2018Q1	us-gaap	Revenues Revenues	22537000000	USD
CY2019Q1	us-gaap	Revenues Revenues	24666000000	USD
CY2018Q4	us-gaap	Securities Held As Collateral At Fair Value SecuritiesHeldAsCollateralAtFairValue	604000000	USD
CY2019Q1	us-gaap	Securities Held As Collateral At Fair Value SecuritiesHeldAsCollateralAtFairValue	591000000	USD
CY2018Q4	us-gaap	Securities Loaned Fair Value Of Collateral SecuritiesLoanedFairValueOfCollateral	604000000	USD
CY2019Q1	us-gaap	Securities Loaned Fair Value Of Collateral SecuritiesLoanedFairValueOfCollateral	590000000	USD
CY2018Q4	us-gaap	Securities Received As Collateral SecuritiesReceivedAsCollateral	604000000	USD
CY2019Q1	us-gaap	Securities Received As Collateral SecuritiesReceivedAsCollateral	591000000	USD
CY2018Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3428000000	USD
CY2019Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3166000000	USD
CY2018Q1	us-gaap	Share Based Compensation ShareBasedCompensation	42000000	USD
CY2019Q1	us-gaap	Share Based Compensation ShareBasedCompensation	70000000	USD
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	0	shares
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	212.54
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	800000	shares
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	500000	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	232.15
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	307.59
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1700000	shares
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1500000	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	183.32
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	239.40
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	700000	shares
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	150.13
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00323
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00260
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.3000
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.2500
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0290
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0269
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2400000	shares
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	135.06
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	0	shares
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	204.80
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	700000	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	55.31
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	68.92
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	423000000	USD
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3700000	shares
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3900000	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	149.65
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	181.02
CY2019Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	121.08
CY2019Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	307.66
CY2018Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P3Y8M12D
CY2019Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y4M24D
CY2019Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y2M28D
CY2019Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y8M16D
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	360000000	USD
CY2018Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	1145000000	USD
CY2019Q1	us-gaap	Short Term Borrowings ShortTermBorrowings	1095000000	USD
CY2019Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	12000000	USD
CY2019Q1	us-gaap	Shortduration Insurance Contracts Liability For Unpaid Claims And Claim Adjustment Expense Other Reconciling Item ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem	214000000	USD
CY2019Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	500000	shares
CY2018Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	28000000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	69000000	USD
CY2018Q1	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount1 StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1	6783000000	USD
CY2019Q1	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount1 StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1	5199000000	USD
CY2018Q1	us-gaap	Stock Repurchased And Retired During Period Shares StockRepurchasedAndRetiredDuringPeriodShares	1700000	shares
CY2019Q1	us-gaap	Stock Repurchased And Retired During Period Shares StockRepurchasedAndRetiredDuringPeriodShares	1100000	shares
CY2018Q1	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	394000000	USD
CY2019Q1	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	294000000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	26503000000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	27012000000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	28541000000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	29998000000	USD
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest Adjusted Balance1 StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1	28567000000	USD
CY2019Q1	us-gaap	Sublease Income SubleaseIncome	4000000	USD
CY2018Q1	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense	16837000000	USD
CY2019Q1	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense	18794000000	USD
CY2018Q1	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense	633000000	USD
CY2019Q1	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense	455000000	USD
CY2018Q1	us-gaap	Supplementary Insurance Information Other Operating Expense SupplementaryInsuranceInformationOtherOperatingExpense	842000000	USD
CY2019Q1	us-gaap	Supplementary Insurance Information Other Operating Expense SupplementaryInsuranceInformationOtherOperatingExpense	943000000	USD
CY2018Q4	us-gaap	Unearned Premiums UnearnedPremiums	902000000	USD
CY2019Q1	us-gaap	Unearned Premiums UnearnedPremiums	998000000	USD
CY2018Q1	us-gaap	Unrealized Gain Loss On Cash Flow Hedging Instruments UnrealizedGainLossOnCashFlowHedgingInstruments	-322000000	USD
CY2019Q1	us-gaap	Unrealized Gain Loss On Cash Flow Hedging Instruments UnrealizedGainLossOnCashFlowHedgingInstruments	-308000000	USD
CY2019Q1	us-gaap	Weighted Average Discount Rate Percent WeightedAverageDiscountRatePercent	0.0397
CY2018Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	7000000	shares

CY2018Q1

antm

Accumulated Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax

AccumulatedOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax

-2000000

USD

CY2019Q1

antm

Accumulated Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax

AccumulatedOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax

-3000000

USD

CY2018Q1

antm

Available For Sale Securities Accumulated Other Comprehensive Income Net Deferred Tax Liability

AvailableForSaleSecuritiesAccumulatedOtherComprehensiveIncomeNetDeferredTaxLiability

-5000000

USD

CY2019Q1

antm

Available For Sale Securities Accumulated Other Comprehensive Income Net Deferred Tax Liability

AvailableForSaleSecuritiesAccumulatedOtherComprehensiveIncomeNetDeferredTaxLiability

-61000000

USD

CY2018Q4

antm

Available For Sale Securities Debt Maturities Amortized Cost Noncurrent

AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostNoncurrent

486000000

USD

CY2019Q1

antm

Available For Sale Securities Debt Maturities Amortized Cost Noncurrent

AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostNoncurrent

482000000

USD

CY2018Q1

antm

Available For Sale Securities Other Than Temporary Impairments In Accumulated Other Comprehensive Income Deferred Tax Liability Asset

AvailableForSaleSecuritiesOtherThanTemporaryImpairmentsInAccumulatedOtherComprehensiveIncomeDeferredTaxLiabilityAsset

0

USD

CY2019Q1

antm

Available For Sale Securities Other Than Temporary Impairments In Accumulated Other Comprehensive Income Deferred Tax Liability Asset

AvailableForSaleSecuritiesOtherThanTemporaryImpairmentsInAccumulatedOtherComprehensiveIncomeDeferredTaxLiabilityAsset

1000000

USD

CY2018Q1

antm

Cash Flow Hedging Instruments Accumulated Other Comprehensive Income Net Deferred Tax Asset

CashFlowHedgingInstrumentsAccumulatedOtherComprehensiveIncomeNetDeferredTaxAsset

67000000

USD

CY2019Q1

antm

Cash Flow Hedging Instruments Accumulated Other Comprehensive Income Net Deferred Tax Asset

CashFlowHedgingInstrumentsAccumulatedOtherComprehensiveIncomeNetDeferredTaxAsset

65000000

USD

CY2019Q1

antm

Percentageofrevenuessubjecttonewrevenueguidanceunder Asc606

PercentageofrevenuessubjecttonewrevenueguidanceunderASC606

0.06

CY2018Q1

antm

Potentially Dilutive Restricted Stock Units Contingent On Operating Results

PotentiallyDilutiveRestrictedStockUnitsContingentOnOperatingResults

300000

shares

CY2019Q1

antm

Self Funded Receivables Net

SelfFundedReceivablesNet

2491000000

USD

CY2018Q1

antm

Deferred Net Actuarial Gain Loss Postretirement Benefits

DeferredNetActuarialGainLossPostretirementBenefits

-77000000

USD

CY2019Q1

antm

Deferred Net Actuarial Gain Loss Postretirement Benefits

DeferredNetActuarialGainLossPostretirementBenefits

-57000000

USD

CY2018Q1

antm

Deferred Prior Service Cost Credit Postretirement Benefit Plans

DeferredPriorServiceCostCreditPostretirementBenefitPlans

43000000

USD

CY2019Q1

antm

Deferred Prior Service Cost Credit Postretirement Benefit Plans

DeferredPriorServiceCostCreditPostretirementBenefitPlans

31000000

USD

CY2018Q1

antm

Defined Benefit Plan Accumulated Other Comprehensive Income Adjustments Net Of Tax

DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeAdjustmentsNetOfTax

-454000000

USD

CY2019Q1

antm

Defined Benefit Plan Accumulated Other Comprehensive Income Adjustments Net Of Tax

DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeAdjustmentsNetOfTax

-554000000

USD

CY2018Q1

antm

Defined Benefit Plan Accumulated Other Comprehensive Income Net Deferred Tax Asset

DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetDeferredTaxAsset

-159000000

USD

CY2019Q1

antm

Defined Benefit Plan Accumulated Other Comprehensive Income Net Deferred Tax Asset

DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetDeferredTaxAsset

-191000000

USD

CY2018Q4

antm

Equity Securities

EquitySecurities

1526000000

USD

CY2019Q1

antm

Equity Securities

EquitySecurities

1244000000

USD

CY2018Q4

antm

Equity Securities Current

EquitySecuritiesCurrent

1493000000

USD

CY2019Q1

antm

Equity Securities Current

EquitySecuritiesCurrent

1211000000

USD

CY2018Q4

antm

Equitysecurities Longterm

EquitysecuritiesLongterm

33000000

USD

CY2019Q1

antm

Equitysecurities Longterm

EquitysecuritiesLongterm

33000000

USD

CY2019Q1

antm

Gross Premium Tax Rate

GrossPremiumTaxRate

0.0235

CY2017Q4

antm

Increase In Stock Repurchase Program Authorization

IncreaseInStockRepurchaseProgramAuthorization

5000000000

USD

CY2019Q1

antm

Lessee Operating Lease Lease Not Yet Commenced Expense

LesseeOperatingLeaseLeaseNotYetCommencedExpense

104000000

USD

CY2018Q4

antm

Liability For Future Policy Benefits Current

LiabilityForFuturePolicyBenefitsCurrent

75000000

USD

CY2019Q1

antm

Liability For Future Policy Benefits Current

LiabilityForFuturePolicyBenefitsCurrent

78000000

USD

CY2018Q1

antm

Liability For Unpaid Claims And Claims Adjustment Expense Purchase Adjustments

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments

199000000

USD

CY2019Q1

antm

Merger Agreement Termination Fee

MergerAgreementTerminationFee

1850000000

USD

CY2018Q1

antm

Netrealizedlossesgainsonfinancialinstruments

-26000000

USD

CY2019Q1

antm

Netrealizedlossesgainsonfinancialinstruments

78000000

USD

CY2019Q1

antm

Number Of Counties In State Of Kansas Company Does Not Serve

NumberOfCountiesInStateOfKansasCompanyDoesNotServe

30

county

CY2019Q1

antm

Number Of Medical Members

NumberOfMedicalMembers

41000000

medical_member

CY2018Q1

antm

Other Net Change In Unrecognized Periodic Benefit Costs For Defined Benefit Pension And Postretirement Benefit Plans Tax Benefit Expense

OtherNetChangeInUnrecognizedPeriodicBenefitCostsForDefinedBenefitPensionAndPostretirementBenefitPlansTaxBenefitExpense

-3000000

USD

CY2019Q1

antm

Other Net Change In Unrecognized Periodic Benefit Costs For Defined Benefit Pension And Postretirement Benefit Plans Tax Benefit Expense

OtherNetChangeInUnrecognizedPeriodicBenefitCostsForDefinedBenefitPensionAndPostretirementBenefitPlansTaxBenefitExpense

-1000000

USD

CY2018Q1

antm

Payments For Proceeds From Financing Derivatives

PaymentsForProceedsFromFinancingDerivatives

-24000000

USD

CY2019Q1

antm

Payments For Proceeds From Financing Derivatives

PaymentsForProceedsFromFinancingDerivatives

0

USD

CY2018Q1

antm

Paymentstoacquireequitysecurities

566000000

USD

CY2019Q1

antm

Paymentstoacquireequitysecurities

3691000000

USD

CY2019Q1

antm

Potentially Dilutive Restricted Stock Units Contingent On Operating Results

PotentiallyDilutiveRestrictedStockUnitsContingentOnOperatingResults

200000

shares

CY2018Q1

antm

Proceedsfromsaleofequitysecurities

1776000000

USD

CY2019Q1

antm

Proceedsfromsaleofequitysecurities

4048000000

USD

CY2017

antm

Reclassificationofstrandedtaxeffectsresultingfromthe Tax Cutsand Jobs Act

ReclassificationofstrandedtaxeffectsresultingfromtheTaxCutsandJobsAct

91000000

USD

CY2019Q1

antm

Securities Lending Transactions Initial Collateral Percentage Value

SecuritiesLendingTransactionsInitialCollateralPercentageValue

1.02

CY2018

antm

Securities Lending Transactions Ratioof Fair Valueof Collateral Held To Securities On Loan

SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan

1.02

CY2019Q1

antm

Securities Lending Transactions Ratioof Fair Valueof Collateral Held To Securities On Loan

SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan

1.03

CY2018Q4

antm

Self Funded Receivables Net

SelfFundedReceivablesNet

2278000000

USD

CY2017Q4

antm

Short Duration Contract Liability For Claims Adjustment Expense

ShortDurationContractLiabilityForClaimsAdjustmentExpense

7814000000

USD

CY2018Q1

antm

Short Duration Contract Liability For Claims Adjustment Expense

ShortDurationContractLiabilityForClaimsAdjustmentExpense

7453000000

USD

CY2018Q4

antm

Short Duration Contract Liability For Claims Adjustment Expense

ShortDurationContractLiabilityForClaimsAdjustmentExpense

7266000000

USD

CY2019Q1

antm

Short Duration Contract Liability For Claims Adjustment Expense

ShortDurationContractLiabilityForClaimsAdjustmentExpense

8028000000

USD

CY2018Q1

antm

Shortdurationcontractliabilityforunpaidclaimsandadjustmentexpense Net

ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet

7419000000

USD

CY2019Q1

antm

Shortdurationcontractliabilityforunpaidclaimsandadjustmentexpense Net

ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet

7994000000

USD

CY2018Q1

antm

Stock Repurchased And Retired During Period Average Price

StockRepurchasedAndRetiredDuringPeriodAveragePrice

233.51

CY2019Q1

antm

Stock Repurchased And Retired During Period Average Price

StockRepurchasedAndRetiredDuringPeriodAveragePrice

275.23

CY2019Q1

dei

Amendment Flag

AmendmentFlag

false

CY2019Q1

dei

Current Fiscal Year End Date

CurrentFiscalYearEndDate

--12-31

CY2019Q1

dei

Document Fiscal Period Focus

DocumentFiscalPeriodFocus

Q1

CY2019Q1

dei

Document Fiscal Year Focus

DocumentFiscalYearFocus

2019

CY2019Q1

dei

Document Period End Date

DocumentPeriodEndDate

2019-03-31

CY2019Q1

dei

Document Type

DocumentType

10-Q

CY2019Q1

dei

Entity Central Index Key

EntityCentralIndexKey

0001156039

CY2019Q2

dei

Entity Common Stock Shares Outstanding

EntityCommonStockSharesOutstanding

257195705

shares

CY2019Q1

dei

Entity Filer Category

EntityFilerCategory

Large Accelerated Filer

CY2019Q1

dei

Entity Registrant Name

EntityRegistrantName

Anthem, Inc.

CY2019Q1

dei

Trading Symbol

TradingSymbol

ANTM

CY2018Q4

us-gaap

Accounts Payable And Accrued Liabilities Current

AccountsPayableAndAccruedLiabilitiesCurrent

4959000000

USD

CY2019Q1

us-gaap

Accounts Payable And Accrued Liabilities Current

AccountsPayableAndAccruedLiabilitiesCurrent

3951000000

USD

CY2018Q4

us-gaap

Accrued Income Taxes Current

AccruedIncomeTaxesCurrent

0

USD

CY2019Q1

us-gaap

Accrued Income Taxes Current

AccruedIncomeTaxesCurrent

105000000

USD

CY2018Q4

us-gaap

Accrued Investment Income Receivable

AccruedInvestmentIncomeReceivable

162000000

USD

CY2019Q1

us-gaap

Accrued Investment Income Receivable

AccruedInvestmentIncomeReceivable

161000000

USD

CY2018Q1

us-gaap

Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax

AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax

14000000

USD

CY2019Q1

us-gaap

Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax

AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax

197000000

USD

CY2018Q1

us-gaap

Accumulated Other Comprehensive Income Loss Cumulative Changes In Net Gain Loss From Cash Flow Hedges Effect Net Of Tax

AccumulatedOtherComprehensiveIncomeLossCumulativeChangesInNetGainLossFromCashFlowHedgesEffectNetOfTax

-255000000

USD

CY2019Q1

us-gaap

Accumulated Other Comprehensive Income Loss Cumulative Changes In Net Gain Loss From Cash Flow Hedges Effect Net Of Tax

AccumulatedOtherComprehensiveIncomeLossCumulativeChangesInNetGainLossFromCashFlowHedgesEffectNetOfTax

-243000000

USD

CY2018Q1

us-gaap

Accumulated Other Comprehensive Income Loss Defined Benefit Pension And Other Postretirement Plans Net Of Tax

AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax

25000000

USD

CY2019Q1

us-gaap

Accumulated Other Comprehensive Income Loss Defined Benefit Pension And Other Postretirement Plans Net Of Tax

AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax

19000000

USD

CY2018Q1

us-gaap

Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax

AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax

-1000000

USD

CY2019Q1

us-gaap

Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax

AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax

-2000000

USD

CY2018Q1

us-gaap

Accumulated Other Comprehensive Income Loss Net Of Tax

AccumulatedOtherComprehensiveIncomeLossNetOfTax

-721000000

USD

CY2018Q4

us-gaap

Accumulated Other Comprehensive Income Loss Net Of Tax

AccumulatedOtherComprehensiveIncomeLossNetOfTax

-986000000

USD

CY2019Q1

us-gaap

Accumulated Other Comprehensive Income Loss Net Of Tax

AccumulatedOtherComprehensiveIncomeLossNetOfTax

-623000000

USD

CY2018Q1

us-gaap

Accumulated Other Comprehensive Income Loss Other Than Temporary Impairment Not Credit Loss Net Of Tax Availableforsale Debt Securities

AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxAvailableforsaleDebtSecurities

0

USD

CY2019Q1

us-gaap

Accumulated Other Comprehensive Income Loss Other Than Temporary Impairment Not Credit Loss Net Of Tax Availableforsale Debt Securities

AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxAvailableforsaleDebtSecurities

3000000

USD

CY2018Q1

us-gaap

Accumulated Other Comprehensive Income Loss Other Than Temporary Impairment Not Credit Loss Net Of Tax Debt Securities

AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities

0

USD

CY2019Q1

us-gaap

Accumulated Other Comprehensive Income Loss Other Than Temporary Impairment Not Credit Loss Net Of Tax Debt Securities

AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities

2000000

USD

CY2018Q4

us-gaap

Additional Paid In Capital

AdditionalPaidInCapital

9536000000

USD

CY2019Q1

us-gaap

Additional Paid In Capital

AdditionalPaidInCapital

9482000000

USD

CY2018Q1

us-gaap

Adjustment For Amortization

AdjustmentForAmortization

240000000

USD

CY2019Q1

us-gaap

Adjustment For Amortization

AdjustmentForAmortization

255000000

USD

CY2018Q1

us-gaap

Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments

AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments

-30000000

USD

CY2019Q1

us-gaap

Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments

AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments

-52000000

USD

CY2018Q1

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

80000000

USD

CY2019Q1

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

87000000

USD

CY2018Q1

us-gaap

Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount

AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

300000

shares

CY2019Q1

us-gaap

Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount

AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

200000

shares

CY2018Q4

us-gaap

Assets

71571000000

USD

CY2019Q1

us-gaap

Assets

74523000000

USD

CY2018Q4

us-gaap

Assets Current

AssetsCurrent

34321000000

USD

CY2019Q1

us-gaap

Assets Current

AssetsCurrent

36611000000

USD

CY2018Q4

us-gaap

Assets Fair Value Disclosure Recurring

AssetsFairValueDisclosureRecurring

21161000000

USD

CY2019Q1

us-gaap

Assets Fair Value Disclosure Recurring

AssetsFairValueDisclosureRecurring

22708000000

USD

CY2018Q4

us-gaap

Available For Sale Debt Securities Amortized Cost Basis

AvailableForSaleDebtSecuritiesAmortizedCostBasis

16894000000

USD

CY2019Q1

us-gaap

Available For Sale Debt Securities Amortized Cost Basis

AvailableForSaleDebtSecuritiesAmortizedCostBasis

17550000000

USD

CY2018Q1

us-gaap

Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax

AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax

239000000

USD

CY2019Q1

us-gaap

Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax

AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax

379000000

USD

CY2018Q1

us-gaap

Available For Sale Securities Accumulated Gross Unrealized Gain Loss Before Tax

AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax

19000000

USD

CY2019Q1

us-gaap

Available For Sale Securities Accumulated Gross Unrealized Gain Loss Before Tax

AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax

258000000

USD

CY2018Q1

us-gaap

Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax

AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax

220000000

USD

CY2019Q1

us-gaap

Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax

AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax

121000000

USD

CY2018Q4

us-gaap

Available For Sale Securities Debt Securities Current

AvailableForSaleSecuritiesDebtSecuritiesCurrent

16692000000

USD

CY2019Q1

us-gaap

Available For Sale Securities Debt Securities Current

AvailableForSaleSecuritiesDebtSecuritiesCurrent

17795000000

USD

CY2018Q4

us-gaap

Available For Sale Securities Debt Securities Noncurrent

AvailableForSaleSecuritiesDebtSecuritiesNoncurrent

487000000

USD

CY2019Q1

us-gaap

Available For Sale Securities Debt Securities Noncurrent

AvailableForSaleSecuritiesDebtSecuritiesNoncurrent

492000000

USD

CY2018Q1

us-gaap

Available For Sale Securities Gross Realized Gains

AvailableForSaleSecuritiesGrossRealizedGains

30000000

USD

CY2019Q1

us-gaap

Available For Sale Securities Gross Realized Gains

AvailableForSaleSecuritiesGrossRealizedGains

18000000

USD

CY2018Q1

us-gaap

Available For Sale Securities Gross Realized Losses

AvailableForSaleSecuritiesGrossRealizedLosses

36000000

USD

CY2019Q1

us-gaap

Available For Sale Securities Gross Realized Losses

AvailableForSaleSecuritiesGrossRealizedLosses

17000000

USD

CY2018Q1

us-gaap

Available For Sale Securities Income Tax Expense On Change In Unrealized Holding Gain Or Loss

AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss

77000000

USD

CY2019Q1

us-gaap

Available For Sale Securities Income Tax Expense On Change In Unrealized Holding Gain Or Loss

AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss

-98000000

USD

CY2018Q1

us-gaap

Benefits Losses And Expenses

BenefitsLossesAndExpenses

20757000000

USD

CY2019Q1

us-gaap

Benefits Losses And Expenses

BenefitsLossesAndExpenses

22721000000

USD

CY2017Q4

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

3609000000

USD

CY2018Q1

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

4631000000

USD

CY2018Q4

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

3934000000

USD

CY2019Q1

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

4482000000

USD

CY2018Q4

us-gaap

Cash And Cash Equivalents Fair Value Disclosure

CashAndCashEquivalentsFairValueDisclosure

1815000000

USD

CY2019Q1

us-gaap

Cash And Cash Equivalents Fair Value Disclosure

CashAndCashEquivalentsFairValueDisclosure

2551000000

USD

CY2018Q1

us-gaap

Cash And Cash Equivalents Period Increase Decrease

CashAndCashEquivalentsPeriodIncreaseDecrease

1022000000

USD

CY2019Q1

us-gaap

Cash And Cash Equivalents Period Increase Decrease

CashAndCashEquivalentsPeriodIncreaseDecrease

548000000

USD

CY2018Q4

us-gaap

Commitments And Contingencies

CommitmentsAndContingencies

USD

CY2019Q1

us-gaap

Commitments And Contingencies

CommitmentsAndContingencies

USD

CY2018Q1

us-gaap

Common Stock Dividends Per Share Cash Paid

CommonStockDividendsPerShareCashPaid

0.75

CY2019Q1

us-gaap

Common Stock Dividends Per Share Cash Paid

CommonStockDividendsPerShareCashPaid

0.8

CY2018Q1

us-gaap

Common Stock Dividends Per Share Declared

CommonStockDividendsPerShareDeclared

0.75

CY2019Q1

us-gaap

Common Stock Dividends Per Share Declared

CommonStockDividendsPerShareDeclared

0.80

CY2018Q4

us-gaap

Common Stock Par Or Stated Value Per Share

CommonStockParOrStatedValuePerShare

0.01

CY2019Q1

us-gaap

Common Stock Par Or Stated Value Per Share

CommonStockParOrStatedValuePerShare

0.01

CY2018Q4

us-gaap

Common Stock Shares Authorized

CommonStockSharesAuthorized

900000000

shares

CY2019Q1

us-gaap

Common Stock Shares Authorized

CommonStockSharesAuthorized

900000000

shares

CY2018Q4

us-gaap

Common Stock Shares Issued

CommonStockSharesIssued

257395577

shares

CY2019Q1

us-gaap

Common Stock Shares Issued

CommonStockSharesIssued

257354383

shares

CY2018Q4

us-gaap

Common Stock Shares Outstanding

CommonStockSharesOutstanding

257395577

shares

CY2019Q1

us-gaap

Common Stock Shares Outstanding

CommonStockSharesOutstanding

257354383

shares

CY2018Q4

us-gaap

Common Stock Value

CommonStockValue

3000000

USD

CY2019Q1

us-gaap

Common Stock Value

CommonStockValue

3000000

USD

CY2018Q1

us-gaap

Comprehensive Income Net Of Tax

ComprehensiveIncomeNetOfTax

1103000000

USD

CY2019Q1

us-gaap

Comprehensive Income Net Of Tax

ComprehensiveIncomeNetOfTax

1914000000

USD

CY2018Q4

us-gaap

Cumulative Effect Of New Accounting Principle In Period Of Adoption

CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption

26000000

USD

CY2018Q1

us-gaap

Cumulative Effect Of New Accounting Principle In Period Of Adoption

CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption

320000000

USD

CY2019Q1

us-gaap

Cumulative Effect Of New Accounting Principle In Period Of Adoption

CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption

26000000

USD

CY2018Q1

us-gaap

Deferred Income Tax Expense Benefit

DeferredIncomeTaxExpenseBenefit

-51000000

USD

CY2019Q1

us-gaap

Deferred Income Tax Expense Benefit

DeferredIncomeTaxExpenseBenefit

55000000

USD

CY2018Q1

us-gaap

Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Postretirement Benefits

DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits

9000000

USD

CY2019Q1

us-gaap

Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Postretirement Benefits

DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits

7000000

USD

CY2018Q1

us-gaap

Deferred Tax Assets Unrealized Currency Losses

DeferredTaxAssetsUnrealizedCurrencyLosses

1000000

USD

CY2019Q1

us-gaap

Deferred Tax Assets Unrealized Currency Losses

DeferredTaxAssetsUnrealizedCurrencyLosses

1000000

USD

CY2018Q4

us-gaap

Deferred Tax Liabilities Noncurrent

DeferredTaxLiabilitiesNoncurrent

1960000000

USD

CY2019Q1

us-gaap

Deferred Tax Liabilities Noncurrent

DeferredTaxLiabilitiesNoncurrent

2116000000

USD

CY2018Q1

us-gaap

Defined Benefit Plan Accumulated Other Comprehensive Income Net Gains Losses Before Tax

DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax

-612000000

USD

CY2019Q1

us-gaap

Defined Benefit Plan Accumulated Other Comprehensive Income Net Gains Losses Before Tax

DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax

-744000000

USD

CY2018Q1

us-gaap

Defined Benefit Plan Accumulated Other Comprehensive Income Net Prior Service Cost Credit Before Tax

DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax

1000000

USD

CY2019Q1

us-gaap

Defined Benefit Plan Accumulated Other Comprehensive Income Net Prior Service Cost Credit Before Tax

DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax

1000000

USD

CY2018Q4

us-gaap

Deposits Received For Securities Loaned At Carrying Value

DepositsReceivedForSecuritiesLoanedAtCarryingValue

604000000

USD

CY2019Q1

us-gaap

Deposits Received For Securities Loaned At Carrying Value

DepositsReceivedForSecuritiesLoanedAtCarryingValue

590000000

USD

CY2018Q1

us-gaap

Depreciation

30000000

USD

CY2019Q1

us-gaap

Depreciation

34000000

USD

CY2018Q1

us-gaap

Dividend Payable Date To Be Paid Day Month And Year

DividendPayableDateToBePaidDayMonthAndYear

2018-03-23

CY2019Q1

us-gaap

Dividend Payable Date To Be Paid Day Month And Year

DividendPayableDateToBePaidDayMonthAndYear

2019-03-29

CY2018Q1

us-gaap

Dividends Common Stock

DividendsCommonStock

198000000

USD

CY2019Q1

us-gaap

Dividends Common Stock

DividendsCommonStock

206000000

USD

CY2018Q1

us-gaap

Dividends Payable Date Declared Day Month And Year

DividendsPayableDateDeclaredDayMonthAndYear

2018-01-30

CY2019Q1

us-gaap

Dividends Payable Date Declared Day Month And Year

DividendsPayableDateDeclaredDayMonthAndYear

2019-01-29

CY2018Q1

us-gaap

Dividends Payable Date Of Record Day Month And Year

DividendsPayableDateOfRecordDayMonthAndYear

2018-03-09

CY2019Q1

us-gaap

Dividends Payable Date Of Record Day Month And Year

DividendsPayableDateOfRecordDayMonthAndYear

2019-03-18

CY2018Q1

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

5.13

CY2019Q1

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

6.03

CY2018Q1

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

4.99

CY2019Q1

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

5.91

CY2018Q1

us-gaap

Effect Of Exchange Rate On Cash And Cash Equivalents

EffectOfExchangeRateOnCashAndCashEquivalents

0

USD

CY2019Q1

us-gaap

Effect Of Exchange Rate On Cash And Cash Equivalents

EffectOfExchangeRateOnCashAndCashEquivalents

-1000000

USD

CY2018Q1

us-gaap

Effective Income Tax Rate Continuing Operations

EffectiveIncomeTaxRateContinuingOperations

0.263

CY2019Q1

us-gaap

Effective Income Tax Rate Continuing Operations

EffectiveIncomeTaxRateContinuingOperations

0.203

CY2018Q1

us-gaap

Fair Value Assets Measured On Recurring Basis Change In Unrealized Gain Loss

FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss

-1000000

USD

CY2019Q1

us-gaap

Fair Value Assets Measured On Recurring Basis Change In Unrealized Gain Loss

FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss

-2000000

USD

CY2018Q1

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1

-239000000

USD

CY2019Q1

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1

-3000000

USD

CY2019Q1

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Other Comprehensive Income Loss

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss

2000000

USD

CY2018Q1

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Purchases

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases

276000000

USD

CY2019Q1

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Purchases

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases

42000000

USD

CY2018Q1

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Sales

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales

5000000

USD

CY2019Q1

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Sales

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales

22000000

USD

CY2018Q1

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Settlements

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements

7000000

USD

CY2019Q1

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Settlements

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements

22000000

USD

CY2018Q1

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3

21000000

USD

CY2019Q1

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3

3000000

USD

CY2018Q1

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3

1000000

USD

CY2019Q1

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3

9000000

USD

CY2017Q4

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue

537000000

USD

CY2018Q1

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue

582000000

USD

CY2018Q4

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue

623000000

USD

CY2019Q1

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue

614000000

USD

CY2018Q1

us-gaap

Gains Losses On Extinguishment Of Debt

GainsLossesOnExtinguishmentOfDebt

-19000000

USD

CY2019Q1

us-gaap

Gains Losses On Extinguishment Of Debt

GainsLossesOnExtinguishmentOfDebt

1000000

USD

CY2018Q4

us-gaap

Goodwill

20504000000

USD

CY2019Q1

us-gaap

Goodwill

20500000000

USD

CY2018Q1

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

1780000000

USD

CY2019Q1

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

1945000000

USD

CY2018Q1

us-gaap

Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments

IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

1780000000

USD

CY2019Q1

us-gaap

Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments

IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

1945000000

USD

CY2018Q1

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

468000000

USD

CY2019Q1

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

394000000

USD

CY2019Q1

us-gaap

Income Tax Reconciliation Nondeductible Expense

IncomeTaxReconciliationNondeductibleExpense

83000000

USD

CY2018Q4

us-gaap

Income Taxes Receivable

IncomeTaxesReceivable

10000000

USD

CY2019Q1

us-gaap

Income Taxes Receivable

IncomeTaxesReceivable

0

USD

CY2018Q1

us-gaap

Increase Decrease In Accounts Payable And Accrued Liabilities

IncreaseDecreaseInAccountsPayableAndAccruedLiabilities

-300000000

USD

CY2019Q1

us-gaap

Increase Decrease In Accounts Payable And Accrued Liabilities

IncreaseDecreaseInAccountsPayableAndAccruedLiabilities

-1029000000

USD

CY2018Q1

us-gaap

Increase Decrease In Collateral Held Under Securities Lending

IncreaseDecreaseInCollateralHeldUnderSecuritiesLending

158000000

USD

CY2019Q1

us-gaap

Increase Decrease In Collateral Held Under Securities Lending

IncreaseDecreaseInCollateralHeldUnderSecuritiesLending

-14000000

USD

CY2018Q1

us-gaap

Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable

IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable

537000000

USD

CY2019Q1

us-gaap

Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable

IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable

115000000

USD

CY2018Q1

us-gaap

Increase Decrease In Insurance Liabilities

IncreaseDecreaseInInsuranceLiabilities

-561000000

USD

CY2019Q1

us-gaap

Increase Decrease In Insurance Liabilities

IncreaseDecreaseInInsuranceLiabilities

791000000

USD

CY2018Q1

us-gaap

Increase Decrease In Other Operating Assets

IncreaseDecreaseInOtherOperatingAssets

392000000

USD

CY2019Q1

us-gaap

Increase Decrease In Other Operating Assets

IncreaseDecreaseInOtherOperatingAssets

125000000

USD

CY2018Q1

us-gaap

Increase Decrease In Other Operating Capital Net

IncreaseDecreaseInOtherOperatingCapitalNet

54000000

USD

CY2019Q1

us-gaap

Increase Decrease In Other Operating Capital Net

IncreaseDecreaseInOtherOperatingCapitalNet

15000000

USD

CY2018Q1

us-gaap

Increase Decrease In Other Operating Liabilities

IncreaseDecreaseInOtherOperatingLiabilities

147000000

USD

CY2019Q1

us-gaap

Increase Decrease In Other Operating Liabilities

IncreaseDecreaseInOtherOperatingLiabilities

675000000

USD

CY2018Q1

us-gaap

Increase Decrease In Outstanding Checks Financing Activities

IncreaseDecreaseInOutstandingChecksFinancingActivities

-124000000

USD

CY2019Q1

us-gaap

Increase Decrease In Outstanding Checks Financing Activities

IncreaseDecreaseInOutstandingChecksFinancingActivities

20000000

USD

CY2018Q1

us-gaap

Increase Decrease In Receivables

IncreaseDecreaseInReceivables

-37000000

USD

CY2019Q1

us-gaap

Increase Decrease In Receivables

IncreaseDecreaseInReceivables

753000000

USD

CY2018Q1

us-gaap

Increase Decrease In Securities Lending Payable

IncreaseDecreaseInSecuritiesLendingPayable

158000000

USD

CY2019Q1

us-gaap

Increase Decrease In Securities Lending Payable

IncreaseDecreaseInSecuritiesLendingPayable

-14000000

USD

CY2018Q1

us-gaap

Increase Decrease In Trading Securities

IncreaseDecreaseInTradingSecurities

7000000

USD

CY2019Q1

us-gaap

Increase Decrease In Trading Securities

IncreaseDecreaseInTradingSecurities

21000000

USD

CY2018Q1

us-gaap

Increase Decrease In Unearned Premiums

IncreaseDecreaseInUnearnedPremiums

1182000000

USD

CY2019Q1

us-gaap

Increase Decrease In Unearned Premiums

IncreaseDecreaseInUnearnedPremiums

96000000

USD

CY2018Q1

us-gaap

Insurance Services Revenue

InsuranceServicesRevenue

22342000000

USD

CY2019Q1

us-gaap

Insurance Services Revenue

InsuranceServicesRevenue

24388000000

USD

CY2018Q4

us-gaap

Intangible Assets Net Excluding Goodwill

IntangibleAssetsNetExcludingGoodwill

9007000000

USD

CY2019Q1

us-gaap

Intangible Assets Net Excluding Goodwill

IntangibleAssetsNetExcludingGoodwill

8925000000

USD

CY2018Q1

us-gaap

Interest Expense

InterestExpense

184000000

USD

CY2019Q1

us-gaap

Interest Expense

InterestExpense

187000000

USD

CY2019Q1

us-gaap

Lease Cost

LeaseCost

53000000

USD

CY2019Q1

us-gaap

Lessee Leasing Arrangements Operating Leases Renewal Term

LesseeLeasingArrangementsOperatingLeasesRenewalTerm

P10Y0M0D

CY2019Q1

us-gaap

Lessee Operating Lease Lease Not Yet Commenced Description

LesseeOperatingLeaseLeaseNotYetCommencedDescription

is expected to commence in 2020 when the construction is completed and we take possession of the building

CY2019Q1

us-gaap

Lessee Operating Lease Lease Not Yet Commenced Term Of Contract

LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract

P12Y0M0D

CY2019Q1

us-gaap

Lessee Operating Lease Liability Payments Due

LesseeOperatingLeaseLiabilityPaymentsDue

821000000

USD

CY2019Q1

us-gaap

Lessee Operating Lease Liability Payments Due After Year Five

LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive

240000000

USD

CY2019Q1

us-gaap

Lessee Operating Lease Liability Payments Due Next Twelve Months

LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths

134000000

USD

CY2019Q1

us-gaap

Lessee Operating Lease Liability Payments Due Year Five

LesseeOperatingLeaseLiabilityPaymentsDueYearFive

84000000

USD

CY2019Q1

us-gaap

Lessee Operating Lease Liability Payments Due Year Four

LesseeOperatingLeaseLiabilityPaymentsDueYearFour

102000000

USD

CY2019Q1

us-gaap

Lessee Operating Lease Liability Payments Due Year Three

LesseeOperatingLeaseLiabilityPaymentsDueYearThree

116000000

USD

CY2019Q1

us-gaap

Lessee Operating Lease Liability Payments Due Year Two

LesseeOperatingLeaseLiabilityPaymentsDueYearTwo

145000000

USD

CY2019Q1

us-gaap

Lessee Operating Lease Liability Undiscounted Excess Amount

LesseeOperatingLeaseLiabilityUndiscountedExcessAmount

127000000

USD

CY2018Q4

us-gaap

Liabilities

43030000000

USD

CY2019Q1

us-gaap

Liabilities

44525000000

USD

CY2018Q4

us-gaap

Liabilities And Stockholders Equity

LiabilitiesAndStockholdersEquity

71571000000

USD

CY2019Q1

us-gaap

Liabilities And Stockholders Equity

LiabilitiesAndStockholdersEquity

74523000000

USD

CY2018Q4

us-gaap

Liabilities Current

LiabilitiesCurrent

21965000000

USD

CY2019Q1

us-gaap

Liabilities Current

LiabilitiesCurrent

22682000000

USD

CY2018Q4

us-gaap

Liabilities Fair Value Disclosure Recurring

LiabilitiesFairValueDisclosureRecurring

17000000

USD

CY2019Q1

us-gaap

Liabilities Fair Value Disclosure Recurring

LiabilitiesFairValueDisclosureRecurring

12000000

USD

CY2018Q4

us-gaap

Liability For Claims And Claims Adjustment Expense

LiabilityForClaimsAndClaimsAdjustmentExpense

7454000000

USD

CY2019Q1

us-gaap

Liability For Claims And Claims Adjustment Expense

LiabilityForClaimsAndClaimsAdjustmentExpense

8242000000

USD

CY2018Q4

us-gaap

Liability For Future Policy Benefits

LiabilityForFuturePolicyBenefits

706000000

USD

CY2019Q1

us-gaap

Liability For Future Policy Benefits

LiabilityForFuturePolicyBenefits

719000000

USD

CY2018Q4

us-gaap

Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense

LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense

10119000000

USD

CY2019Q1

us-gaap

Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense

LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense

10897000000

USD

CY2018Q1

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1

11204000000

USD

CY2019Q1

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1

12163000000

USD

CY2018Q1

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1

5489000000

USD

CY2019Q1

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1

5414000000

USD

CY2018Q1

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1

16204000000

USD

CY2019Q1

us-gaap

Net Cash Provided By Used In Investing Activities

NetCashProvidedByUsedInInvestingActivities

-652000000

USD

CY2019Q1

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1

18339000000

USD

CY2017Q4

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Net

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet

7709000000

USD

CY2018Q4

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Net

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet

7232000000

USD

CY2019Q1

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Net

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet

7994000000

USD

CY2018Q4

us-gaap

Long Term Debt Current

LongTermDebtCurrent

849000000

USD

CY2019Q1

us-gaap

Long Term Debt Current

LongTermDebtCurrent

851000000

USD

CY2018Q4

us-gaap

Long Term Debt Noncurrent

LongTermDebtNoncurrent

17217000000

USD

CY2019Q1

us-gaap

Long Term Debt Noncurrent

LongTermDebtNoncurrent

17396000000

USD

CY2018Q1

us-gaap

Net Cash Provided By Used In Financing Activities

NetCashProvidedByUsedInFinancingActivities

-627000000

USD

CY2019Q1

us-gaap

Net Cash Provided By Used In Financing Activities

NetCashProvidedByUsedInFinancingActivities

-429000000

USD

CY2018Q1

us-gaap

Net Cash Provided By Used In Investing Activities

NetCashProvidedByUsedInInvestingActivities

-566000000

USD

CY2018Q1

us-gaap

Net Cash Provided By Used In Operating Activities

NetCashProvidedByUsedInOperatingActivities

2215000000

USD

CY2019Q1

us-gaap

Net Cash Provided By Used In Operating Activities

NetCashProvidedByUsedInOperatingActivities

1630000000

USD

CY2018Q1

us-gaap

Net Income Loss

NetIncomeLoss

1312000000

USD

CY2019Q1

us-gaap

Net Income Loss

NetIncomeLoss

1551000000

USD

CY2018Q1

us-gaap

Net Investment Income

NetInvestmentIncome

229000000

USD

CY2019Q1

us-gaap

Net Investment Income

NetInvestmentIncome

210000000

USD

CY2019Q1

us-gaap

Number Of Reportable Segments

NumberOfReportableSegments

3

segment

CY2019Q1

us-gaap

Number Of States In Which Entity Operates

NumberOfStatesInWhichEntityOperates

50

states

CY2018Q1

us-gaap

Operating Income Loss

OperatingIncomeLoss

1868000000

USD

CY2019Q1

us-gaap

Operating Income Loss

OperatingIncomeLoss

1940000000

USD

CY2019Q1

us-gaap

Operating Lease Cost

OperatingLeaseCost

45000000

USD

CY2019Q1

us-gaap

Operating Lease Liability

OperatingLeaseLiability

694000000

USD

CY2019Q1

us-gaap

Operating Lease Liability

OperatingLeaseLiability

728000000

USD

CY2019Q1

us-gaap

Operating Lease Payments

OperatingLeasePayments

44000000

USD

CY2019Q1

us-gaap

Operating Lease Right Of Use Asset

OperatingLeaseRightOfUseAsset

637000000

USD

CY2019Q1

us-gaap

Operating Lease Weighted Average Remaining Lease Term

OperatingLeaseWeightedAverageRemainingLeaseTerm

P6Y6M0D

CY2018Q4

us-gaap

Other Assets Current

OtherAssetsCurrent

2104000000

USD

CY2019Q1

us-gaap

Other Assets Current

OtherAssetsCurrent

2172000000

USD

CY2018Q4

us-gaap

Other Assets Noncurrent

OtherAssetsNoncurrent

758000000

USD

CY2019Q1

us-gaap

Other Assets Noncurrent

OtherAssetsNoncurrent

1453000000

USD

CY2018Q1

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax

-256000000

USD

CY2019Q1

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax

350000000

USD

CY2018Q1

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

-209000000

USD

CY2019Q1

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

363000000

USD

CY2018Q1

us-gaap

Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent

OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent

-209000000

USD

CY2019Q1

us-gaap

Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent

OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent

363000000

USD

CY2018Q1

us-gaap

Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax

OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax

-7000000

USD

CY2019Q1

us-gaap

Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax

OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax

-3000000

USD

CY2018Q1

us-gaap

Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax

OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax

-11000000

USD

CY2019Q1

us-gaap

Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax

OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax

-7000000

USD

CY2018Q1

us-gaap

Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax

OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax

-3000000

USD

CY2019Q1

us-gaap

Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax

OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax

-2000000

USD

CY2018Q1

us-gaap

Other Comprehensive Income Loss Tax

OtherComprehensiveIncomeLossTax

63000000

USD

CY2019Q1

us-gaap

Other Comprehensive Income Loss Tax

OtherComprehensiveIncomeLossTax

-101000000

USD

CY2018Q1

us-gaap

Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax

OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax

29000000

USD

CY2019Q1

us-gaap

Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax

OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax

3000000

USD

CY2018Q1

us-gaap

Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax

OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax

-8000000

USD

CY2019Q1

us-gaap

Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax

OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax

0

USD

CY2018Q1

us-gaap

Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax

OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax

-245000000

USD

CY2019Q1

us-gaap

Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax

OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax

357000000

USD

CY2018Q1

us-gaap

Other Income

OtherIncome

1439000000

USD

CY2019Q1

us-gaap

Other Income

OtherIncome

1545000000

USD

CY2018Q4

us-gaap

Other Liabilities Current

OtherLiabilitiesCurrent

3190000000

USD

CY2019Q1

us-gaap

Other Liabilities Current

OtherLiabilitiesCurrent

4037000000

USD

CY2018Q4

us-gaap

Other Liabilities Noncurrent

OtherLiabilitiesNoncurrent

1182000000

USD

CY2019Q1

us-gaap

Other Liabilities Noncurrent

OtherLiabilitiesNoncurrent

1612000000

USD

CY2018Q4

us-gaap

Other Long Term Investments

OtherLongTermInvestments

3726000000

USD

CY2019Q1

us-gaap

Other Long Term Investments

OtherLongTermInvestments

3710000000

USD

CY2018Q4

us-gaap

Other Policyholder Funds

OtherPolicyholderFunds

2590000000

USD

CY2019Q1

us-gaap

Other Policyholder Funds

OtherPolicyholderFunds

2577000000

USD

CY2018Q4

us-gaap

Other Receivables

OtherReceivables

2558000000

USD

CY2019Q1

us-gaap

Other Receivables

OtherReceivables

2639000000

USD

CY2018Q4

us-gaap

Other Short Term Investments

OtherShortTermInvestments

21000000

USD

CY2019Q1

us-gaap

Other Short Term Investments

OtherShortTermInvestments

20000000

USD

CY2018Q1

us-gaap

Other Than Temporary Impairment Losses Investments Availableforsale Securities

OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities

8000000

USD

CY2019Q1

us-gaap

Other Than Temporary Impairment Losses Investments Availableforsale Securities

OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities

13000000

USD

CY2018Q1

us-gaap

Other Than Temporary Impairment Losses Investments Portion In Other Comprehensive Income Loss Before Tax Including Portion Attributable To Noncontrolling Interest Availableforsale Securities

OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossBeforeTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities

0

USD

CY2019Q1

us-gaap

Other Than Temporary Impairment Losses Investments Portion In Other Comprehensive Income Loss Before Tax Including Portion Attributable To Noncontrolling Interest Availableforsale Securities

OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossBeforeTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities

-3000000

USD

CY2018Q1

us-gaap

Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net

OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet

8000000

USD

CY2019Q1

us-gaap

Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net

OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet

10000000

USD

CY2018Q4

us-gaap

Payables To Broker Dealers And Clearing Organizations

PayablesToBrokerDealersAndClearingOrganizations

197000000

USD

CY2019Q1

us-gaap

Payables To Broker Dealers And Clearing Organizations

PayablesToBrokerDealersAndClearingOrganizations

158000000

USD

CY2018Q1

us-gaap

Payments For Losses And Loss Adjustment Expense

PaymentsForLossesAndLossAdjustmentExpense

16693000000

USD

CY2019Q1

us-gaap

Payments For Losses And Loss Adjustment Expense

PaymentsForLossesAndLossAdjustmentExpense

17577000000

USD

CY2018Q1

us-gaap

Payments For Proceeds From Other Investing Activities

PaymentsForProceedsFromOtherInvestingActivities

-4000000

USD

CY2019Q1

us-gaap

Payments For Proceeds From Other Investing Activities

PaymentsForProceedsFromOtherInvestingActivities

-8000000

USD

CY2018Q1

us-gaap

Payments For Repurchase Of Common Stock

PaymentsForRepurchaseOfCommonStock

395000000

USD

CY2019Q1

us-gaap

Payments For Repurchase Of Common Stock

PaymentsForRepurchaseOfCommonStock

294000000

USD

CY2018Q1

us-gaap

Payments Of Dividends

PaymentsOfDividends

192000000

USD

CY2019Q1

us-gaap

Payments Of Dividends

PaymentsOfDividends

206000000

USD

CY2018Q1

us-gaap

Payments Related To Tax Withholding For Share Based Compensation

PaymentsRelatedToTaxWithholdingForShareBasedCompensation

73000000

USD

CY2019Q1

us-gaap

Payments Related To Tax Withholding For Share Based Compensation

PaymentsRelatedToTaxWithholdingForShareBasedCompensation

78000000

USD

CY2018Q1

us-gaap

Payments To Acquire Available For Sale Securities Debt

PaymentsToAcquireAvailableForSaleSecuritiesDebt

2236000000

USD

CY2019Q1

us-gaap

Payments To Acquire Available For Sale Securities Debt

PaymentsToAcquireAvailableForSaleSecuritiesDebt

2300000000

USD

CY2018Q1

us-gaap

Payments To Acquire Businesses Net Of Cash Acquired

PaymentsToAcquireBusinessesNetOfCashAcquired

1346000000

USD

CY2019Q1

us-gaap

Payments To Acquire Businesses Net Of Cash Acquired

PaymentsToAcquireBusinessesNetOfCashAcquired

0

USD

CY2018Q1

us-gaap

Payments To Acquire Other Investments

PaymentsToAcquireOtherInvestments

72000000

USD

CY2019Q1

us-gaap

Payments To Acquire Other Investments

PaymentsToAcquireOtherInvestments

78000000

USD

CY2018Q1

us-gaap

Payments To Acquire Property Plant And Equipment

PaymentsToAcquirePropertyPlantAndEquipment

218000000

USD

CY2019Q1

us-gaap

Payments To Acquire Property Plant And Equipment

PaymentsToAcquirePropertyPlantAndEquipment

234000000

USD

CY2018Q1

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

17046000000

USD

CY2019Q1

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

19282000000

USD

CY2018Q4

us-gaap

Preferred Stock Par Or Stated Value Per Share

PreferredStockParOrStatedValuePerShare

0

CY2019Q1

us-gaap

Preferred Stock Par Or Stated Value Per Share

PreferredStockParOrStatedValuePerShare

0

CY2018Q4

us-gaap

Preferred Stock Shares Authorized

PreferredStockSharesAuthorized

100000000

shares

CY2019Q1

us-gaap

Preferred Stock Shares Authorized

PreferredStockSharesAuthorized

100000000

shares

CY2018Q4

us-gaap

Preferred Stock Shares Issued

PreferredStockSharesIssued

0

shares

CY2019Q1

us-gaap

Preferred Stock Shares Issued

PreferredStockSharesIssued

0

shares

CY2018Q4

us-gaap

Preferred Stock Shares Outstanding

PreferredStockSharesOutstanding

0

shares

CY2019Q1

us-gaap

Preferred Stock Shares Outstanding

PreferredStockSharesOutstanding

0

shares

CY2018Q4

us-gaap

Preferred Stock Value

PreferredStockValue

0

USD

CY2019Q1

us-gaap

Preferred Stock Value

PreferredStockValue

0

USD

CY2018Q1

us-gaap

Premiums Earned Net

PremiumsEarnedNet

20903000000

USD

CY2019Q1

us-gaap

Premiums Earned Net

PremiumsEarnedNet

22843000000

USD

CY2018Q4

us-gaap

Premiums Receivable At Carrying Value

PremiumsReceivableAtCarryingValue

4465000000

USD

CY2019Q1

us-gaap

Premiums Receivable At Carrying Value

PremiumsReceivableAtCarryingValue

5049000000

USD

CY2018Q1

us-gaap

Proceeds From Issuance Of Long Term Debt

ProceedsFromIssuanceOfLongTermDebt

836000000

USD

CY2019Q1

us-gaap

Proceeds From Issuance Of Long Term Debt

ProceedsFromIssuanceOfLongTermDebt

2000000

USD

CY2018Q1

us-gaap

Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities

ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities

363000000

USD

CY2019Q1

us-gaap

Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities

ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities

393000000

USD

CY2018Q1

us-gaap

Proceeds From Repayments Of Commercial Paper

ProceedsFromRepaymentsOfCommercialPaper

-108000000

USD

CY2019Q1

us-gaap

Proceeds From Repayments Of Commercial Paper

ProceedsFromRepaymentsOfCommercialPaper

178000000

USD

CY2018Q1

us-gaap

Proceeds From Sale And Maturity Of Other Investments

ProceedsFromSaleAndMaturityOfOtherInvestments

23000000

USD

CY2019Q1

us-gaap

Proceeds From Sale And Maturity Of Other Investments

ProceedsFromSaleAndMaturityOfOtherInvestments

113000000

USD

CY2018Q1

us-gaap

Proceeds From Sale Of Available For Sale Securities

ProceedsFromSaleOfAvailableForSaleSecurities

2227000000

USD

CY2019Q1

us-gaap

Proceeds From Sale Of Available For Sale Securities

ProceedsFromSaleOfAvailableForSaleSecurities

1468000000

USD

CY2018Q1

us-gaap

Proceeds From Sale Of Available For Sale Securities Debt

ProceedsFromSaleOfAvailableForSaleSecuritiesDebt

1864000000

USD

CY2019Q1

us-gaap

Proceeds From Sale Of Available For Sale Securities Debt

ProceedsFromSaleOfAvailableForSaleSecuritiesDebt

1075000000

USD

CY2018Q1

us-gaap

Proceeds From Short Term Debt

ProceedsFromShortTermDebt

1505000000

USD

CY2019Q1

us-gaap

Proceeds From Short Term Debt

ProceedsFromShortTermDebt

2710000000

USD

CY2018Q1

us-gaap

Proceeds From Stock Options Exercised

ProceedsFromStockOptionsExercised

60000000

USD

CY2019Q1

us-gaap

Proceeds From Stock Options Exercised

ProceedsFromStockOptionsExercised

76000000

USD

CY2018Q4

us-gaap

Property Plant And Equipment Net

PropertyPlantAndEquipmentNet

2735000000

USD

CY2019Q1

us-gaap

Property Plant And Equipment Net

PropertyPlantAndEquipmentNet

2799000000

USD

CY2017Q4

us-gaap

Reinsurance Recoverable For Unpaid Claims And Claims Adjustments

ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments

105000000

USD

CY2018Q1

us-gaap

Reinsurance Recoverable For Unpaid Claims And Claims Adjustments

ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments

34000000

USD

CY2018Q4

us-gaap

Reinsurance Recoverable For Unpaid Claims And Claims Adjustments

ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments

34000000

USD

CY2019Q1

us-gaap

Reinsurance Recoverable For Unpaid Claims And Claims Adjustments

ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments

34000000

USD

CY2018Q1

us-gaap

Repayments Of Long Term Debt

RepaymentsOfLongTermDebt

663000000

USD

CY2019Q1

us-gaap

Repayments Of Long Term Debt

RepaymentsOfLongTermDebt

63000000

USD

CY2018Q1

us-gaap

Repayments Of Short Term Debt

RepaymentsOfShortTermDebt

1655000000

USD

CY2019Q1

us-gaap

Repayments Of Short Term Debt

RepaymentsOfShortTermDebt

2760000000

USD

CY2018Q4

us-gaap

Restricted Cash And Investments Current

RestrictedCashAndInvestmentsCurrent

222000000

USD

CY2019Q1

us-gaap

Restricted Cash And Investments Current

RestrictedCashAndInvestmentsCurrent

262000000

USD

CY2018Q4

us-gaap

Retained Earnings Accumulated Deficit

RetainedEarningsAccumulatedDeficit

19988000000

USD

CY2019Q1

us-gaap

Retained Earnings Accumulated Deficit

RetainedEarningsAccumulatedDeficit

21136000000

USD

CY2018Q1

us-gaap

Revenues

22537000000

USD

CY2019Q1

us-gaap

Revenues

24666000000

USD

CY2018Q4

us-gaap

Securities Held As Collateral At Fair Value

SecuritiesHeldAsCollateralAtFairValue

604000000

USD

CY2019Q1

us-gaap

Securities Held As Collateral At Fair Value

SecuritiesHeldAsCollateralAtFairValue

591000000

USD

CY2018Q4

us-gaap

Securities Loaned Fair Value Of Collateral

SecuritiesLoanedFairValueOfCollateral

604000000

USD

CY2019Q1

us-gaap

Securities Loaned Fair Value Of Collateral

SecuritiesLoanedFairValueOfCollateral

590000000

USD

CY2018Q4

us-gaap

Securities Received As Collateral

SecuritiesReceivedAsCollateral

604000000

USD

CY2019Q1

us-gaap

Securities Received As Collateral

SecuritiesReceivedAsCollateral

591000000

USD

CY2018Q1

us-gaap

Selling General And Administrative Expense

SellingGeneralAndAdministrativeExpense

3428000000

USD

CY2019Q1

us-gaap

Selling General And Administrative Expense

SellingGeneralAndAdministrativeExpense

3166000000

USD

CY2018Q1

us-gaap

Share Based Compensation

ShareBasedCompensation

42000000

USD

CY2019Q1

us-gaap

Share Based Compensation

ShareBasedCompensation

70000000

USD

CY2019Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod

0

shares

CY2019Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue

212.54

CY2018Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

800000

shares

CY2019Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

500000

shares

CY2018Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

232.15

CY2019Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

307.59

CY2018Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber

1700000

shares

CY2019Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber

1500000

shares

CY2018Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue

183.32

CY2019Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue

239.40

CY2019Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod

700000

shares

CY2019Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue

150.13

CY2018Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

0.00323

CY2019Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

0.00260

CY2018Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

0.3000

CY2019Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

0.2500

CY2018Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

0.0290

CY2019Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

0.0269

CY2019Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

2400000

shares

CY2019Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

135.06

CY2019Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod

0

shares

CY2019Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice

204.80

CY2019Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod

700000

shares

CY2018Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

55.31

CY2019Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

68.92

CY2019Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

423000000

USD

CY2018Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

3700000

shares

CY2019Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

3900000

shares

CY2018Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

149.65

CY2019Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

181.02

CY2019Q1

us-gaap

Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

121.08

CY2019Q1

us-gaap

Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

307.66

CY2018Q1

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1

SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

P3Y8M12D

CY2019Q1

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1

SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

P4Y4M24D

CY2019Q1

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1

P5Y2M28D

CY2019Q1

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

P6Y8M16D

CY2019Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue

360000000

USD

CY2018Q4

us-gaap

Short Term Borrowings

ShortTermBorrowings

1145000000

USD

CY2019Q1

us-gaap

Short Term Borrowings

ShortTermBorrowings

1095000000

USD

CY2019Q1

us-gaap

Short Term Lease Cost

ShortTermLeaseCost

12000000

USD

CY2019Q1

us-gaap

Shortduration Insurance Contracts Liability For Unpaid Claims And Claim Adjustment Expense Other Reconciling Item

ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem

214000000

USD

CY2019Q1

us-gaap

Stock Issued During Period Shares Stock Options Exercised

StockIssuedDuringPeriodSharesStockOptionsExercised

500000

shares

CY2018Q1

us-gaap

Stock Issued During Period Value Stock Options Exercised

StockIssuedDuringPeriodValueStockOptionsExercised

28000000

USD

CY2019Q1

us-gaap

Stock Issued During Period Value Stock Options Exercised

StockIssuedDuringPeriodValueStockOptionsExercised

69000000

USD

CY2018Q1

us-gaap

Stock Repurchase Program Remaining Authorized Repurchase Amount1

StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1

6783000000

USD

CY2019Q1

us-gaap

Stock Repurchase Program Remaining Authorized Repurchase Amount1

StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1

5199000000

USD

CY2018Q1

us-gaap

Stock Repurchased And Retired During Period Shares

StockRepurchasedAndRetiredDuringPeriodShares

1700000

shares

CY2019Q1

us-gaap

Stock Repurchased And Retired During Period Shares

StockRepurchasedAndRetiredDuringPeriodShares

1100000

shares

CY2018Q1

us-gaap

Stock Repurchased And Retired During Period Value

StockRepurchasedAndRetiredDuringPeriodValue

394000000

USD

CY2019Q1

us-gaap

Stock Repurchased And Retired During Period Value

StockRepurchasedAndRetiredDuringPeriodValue

294000000

USD

CY2017Q4

us-gaap

Stockholders Equity

StockholdersEquity

26503000000

USD

CY2018Q1

us-gaap

Stockholders Equity

StockholdersEquity

27012000000

USD

CY2018Q4

us-gaap

Stockholders Equity

StockholdersEquity

28541000000

USD

CY2019Q1

us-gaap

Stockholders Equity

StockholdersEquity

29998000000

USD

CY2018Q4

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest Adjusted Balance1

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1

28567000000

USD

CY2019Q1

us-gaap

Sublease Income

SubleaseIncome

4000000

USD

CY2018Q1

us-gaap

Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense

SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense

16837000000

USD

CY2019Q1

us-gaap

Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense

SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense

18794000000

USD

CY2018Q1

us-gaap

Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense

SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense

633000000

USD

CY2019Q1

us-gaap

Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense

SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense

455000000

USD

CY2018Q1

us-gaap

Supplementary Insurance Information Other Operating Expense

SupplementaryInsuranceInformationOtherOperatingExpense

842000000

USD

CY2019Q1

us-gaap

Supplementary Insurance Information Other Operating Expense

SupplementaryInsuranceInformationOtherOperatingExpense

943000000

USD

CY2018Q4

us-gaap

Unearned Premiums

UnearnedPremiums

902000000

USD

CY2019Q1

us-gaap

Unearned Premiums

UnearnedPremiums

998000000

USD

CY2018Q1

us-gaap

Unrealized Gain Loss On Cash Flow Hedging Instruments

UnrealizedGainLossOnCashFlowHedgingInstruments

-322000000

USD

CY2019Q1

us-gaap

Unrealized Gain Loss On Cash Flow Hedging Instruments

UnrealizedGainLossOnCashFlowHedgingInstruments

-308000000

USD

CY2019Q1

us-gaap

Weighted Average Discount Rate Percent

WeightedAverageDiscountRatePercent

0.0397

CY2018Q1

us-gaap

Weighted Average Number Diluted Shares Outstanding Adjustment

WeightedAverageNumberDilutedSharesOutstandingAdjustment

7000000

shares

CY2019Q1

us-gaap

Weighted Average Number Diluted Shares Outstanding Adjustment

WeightedAverageNumberDilutedSharesOutstandingAdjustment

5200000

shares

CY2018Q1

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

262800000

shares

CY2019Q1

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

262300000

shares

CY2018Q1

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

255800000

shares

CY2019Q1

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

257100000

shares

CY2019Q1

us-gaap

Description Of New Accounting Pronouncements Not Yet Adopted

DescriptionOfNewAccountingPronouncementsNotYetAdopted

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Guidance Not Yet Adopted: </font><font style="font-family:inherit;font-size:10pt;">In November 2018, the FASB issued Accounting Standards Update No. 2018-19, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Codification Improvements to Topic 326, Financial Instruments - Credit Losses,</font><font style="font-family:inherit;font-size:10pt;"> or ASU 2018-19. The amendments in ASU 2018-19 provide additional clarification and implementation guidance on certain aspects of the previously issued Accounting Standards Update No. 2016-13, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,</font><font style="font-family:inherit;font-size:10pt;"> or ASU 2016-13, and have the same effective date and transition requirements as ASU 2016-13. ASU 2016-13 introduces a current expected credit loss model for measuring expected credit losses for certain types of financial instruments held at the reporting date based on historical experience, current conditions and reasonable supportable forecasts. ASU 2016-13 replaces the current incurred loss model for measuring expected credit losses, requires expected losses on available-for-sale debt securities to be recognized through an allowance for credit losses rather than as reductions in the amortized cost of the securities and provides for additional disclosure requirements. ASU 2016-13 is effective for us on January 1, 2020, with early adoption permitted. We are currently evaluating the effects the adoption of ASU 2016-13 will have on our consolidated financial statements, results of operations and cash flows.</font></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued Accounting Standards Update No. 2018-15, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract</font><font style="font-family:inherit;font-size:10pt;">, or ASU 2018-15. The amendments in ASU 2018-15 require implementation costs incurred by customers in cloud computing arrangements to be deferred and recognized over the term of the arrangement, if those costs would be capitalized by the customer in a software licensing arrangement under the internal-use software guidance. The amendments also require an entity to disclose the nature of its hosting arrangements and adhere to certain presentation requirements in its balance sheet, income statement and statement of cash flows. ASU 2018-15 is effective for us on January 1, 2020, with early adoption permitted. The guidance can be applied either prospectively to all implementation costs incurred after the date of adoption or retrospectively. We are currently evaluating the effects the adoption of ASU 2018-15 will have on our consolidated financial position, results of operations and cash flows.</font></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued Accounting Standards Update No. 2018-14, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation—Retirement Benefits - Defined Benefit Plans—General (Subtopic 715-20): Disclosure Framework—Changes to the Disclosure Requirements for Defined Benefit Plans</font><font style="font-family:inherit;font-size:10pt;">, or ASU 2018-14. The amendments in ASU 2018-14 eliminate, add, and modify certain disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans. The amendments are effective for our annual reporting periods beginning after December 15, 2020, with early adoption permitted. The guidance is to be applied on a retrospective basis to all periods presented. We are currently evaluating the effects the adoption of ASU 2018-14 will have on our disclosures.</font></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued Accounting Standards Update No. 2018-12,</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> Financial Services—Insurance (Topic 944): Targeted Improvements to the Accounting for Long-Duration Contracts, </font><font style="font-family:inherit;font-size:10pt;">or ASU 2018-12. The amendments in ASU 2018-12 make changes to a variety of areas to simplify or improve the existing recognition, measurement, presentation and disclosure requirements for long-duration contracts issued by an insurance entity. The amendments require insurers to annually review the assumptions they make about their policyholders and update the liabilities for future policy benefits if the assumptions change. The amendments also simplify the amortization of deferred contract acquisition costs and add new disclosure requirements about the assumptions insurers use to measure their liabilities and how they may affect future cash flows. The amendments in ASU 2018-12 will be effective for our interim and annual reporting periods beginning after December 15, 2020. The amendments related to the liability for future policy benefits for traditional and limited-payment contracts and deferred acquisition costs are to be applied to contracts in force as of the beginning of the earliest period presented, with an option to apply such amendments retrospectively with a cumulative-effect adjustment to the opening balance of retained earnings as of the earliest period presented. The amendments for market risk benefits are to be applied retrospectively. We are currently evaluating the effects the adoption of ASU 2018-12 will have on our consolidated financial position, results of operations, cash flows, and related disclosures.</font></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, the FASB issued Accounting Standards Update No. 2017-04, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment</font><font style="font-family:inherit;font-size:10pt;">, or ASU 2017-04. This update removes Step 2 of the goodwill impairment test under current guidance, which requires a hypothetical purchase price allocation. The new guidance requires an impairment charge to be recognized for the amount by which the carrying amount exceeds the reporting unit's fair value. Upon adoption, the guidance is to be applied prospectively. ASU 2017-04 is effective for us on January 1, 2020, with early adoption permitted. The adoption of ASU 2017-04 is not expected to have a material impact on our consolidated financial position, results of operations or cash flows.</font></div><div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There were no other new accounting pronouncements that were issued or became effective since the issuance of our </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> Annual Report on Form 10-K that had, or are expected to have, a material impact on our consolidated financial position, results of operations or cash flows.</font></div></div>

CY2019Q1

us-gaap

Nature Of Operations

NatureOfOperations

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Organization</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">References to the terms “we,” “our,” “us” or “Anthem” used throughout these Notes to Consolidated Financial Statements refer to Anthem, Inc., an Indiana corporation, and unless the context otherwise requires, its direct and indirect subsidiaries. References to the “states” include the District of Columbia, unless the context otherwise requires.</font></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are one of the largest health benefits companies in the United States in terms of medical membership, serving approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">41</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">medical members through our affiliated health plans as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;">. We offer a broad spectrum of network-based managed care plans to Large Group, Small Group, Individual, Medicaid and Medicare markets. Our managed care plans include: Preferred Provider Organizations, or PPOs; Health Maintenance Organizations, or HMOs; Point-of-Service, or POS, plans; traditional indemnity plans and other hybrid plans, including Consumer-Driven Health Plans, or CDHPs; and hospital only and limited benefit products. In addition, we provide a broad array of managed care services to self-funded customers, including claims processing, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness programs and other administrative services. We provide an array of specialty and other insurance products and services such as dental, vision, life and disability insurance benefits, radiology benefit management and analytics-driven personal health care. We also provide services to the federal government in connection with the Federal Employee Program</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are an independent licensee of the Blue Cross and Blue Shield Association, or BCBSA, an association of independent health benefit plans. </font><font style="font-family:inherit;font-size:10pt;">We serve our members as the Blue Cross licensee for California and as the Blue Cross and Blue Shield, or BCBS, licensee for Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (excluding </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">30</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">counties in the Kansas City area), Nevada, New Hampshire, New York (in the New York City metropolitan area and upstate New York), Ohio, Virginia (excluding the Northern Virginia suburbs of Washington, D.C.) and Wisconsin. In a majority of these service areas, we do business as Anthem Blue Cross, Anthem Blue Cross and Blue Shield, and Empire Blue Cross Blue Shield or Empire Blue Cross. We also conduct business through arrangements with other BCBS licensees. Through our subsidiaries, we also serve customers in numerous </font><font style="font-family:inherit;font-size:10pt;">states across the country as America’s 1st Choice, Amerigroup, Aspire Health, CareMore, Freedom Health, HealthLink, HealthSun, Optimum HealthCare, Simply Healthcare, and/or Unicare.</font><font style="font-family:inherit;font-size:10pt;"> We are licensed to conduct insurance operations in all </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">50</font><font style="font-family:inherit;font-size:10pt;"> states and the District of Columbia through our subsidiaries.</font></div></div>

CY2019Q1

us-gaap

Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense

ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:4px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A reconciliation of the beginning and ending balances for medical claims payable, by segment (see Note 15, “Segment Information”), for the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> is as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.60317460317461%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:65%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Commercial</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">& Specialty</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Business</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Government</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Business</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross medical claims payable, beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,586</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,680</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,266</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ceded medical claims payable, beginning of period</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(24</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net medical claims payable, beginning of period</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,576</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,656</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,232</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net incurred medical claims:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current period</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,695</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,099</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,794</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior periods redundancies</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(197</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(258</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(455</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total net incurred medical claims</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,498</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,841</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,339</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net payments attributable to:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current period medical claims</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,540</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,623</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,163</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior periods medical claims</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,766</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,648</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,414</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total net payments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,306</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,271</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,577</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net medical claims payable, end of period</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,768</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,226</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,994</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ceded medical claims payable, end of period</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross medical claims payable, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,776</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,252</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,028</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;">, the total of net incurred but not reported liabilities plus expected development on reported claims for the Commercial & Specialty Business was </font><font style="font-family:inherit;font-size:10pt;">$87</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$526</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$2,155</font><font style="font-family:inherit;font-size:10pt;"> for the claim years 2017 and prior, 2018 and 2019, respectively.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;">, the total of net incurred but not reported liabilities plus expected development on reported claims for the Government Business was </font><font style="font-family:inherit;font-size:10pt;">$51</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$699</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$4,476</font><font style="font-family:inherit;font-size:10pt;"> for the claim years 2017 and prior, 2018 and 2019, respectively.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A reconciliation of the beginning and ending balances for medical claims payable, by segment (see Note 15, “Segment Information”), for the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> is as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.60317460317461%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:65%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Commercial</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">& Specialty</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Business</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Government</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Business</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross medical claims payable, beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,383</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,431</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,814</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ceded medical claims payable, beginning of period</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(78</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(105</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net medical claims payable, beginning of period</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,305</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,404</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,709</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Business combinations and purchase adjustments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">199</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">199</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net incurred medical claims:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current period</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,745</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,092</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,837</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior periods redundancies</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(335</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(298</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(633</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total net incurred medical claims</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,410</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,794</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,204</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net payments attributable to:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current period medical claims</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,739</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,465</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,204</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior periods medical claims</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,204</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,285</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,489</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total net payments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,943</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,750</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,693</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net medical claims payable, end of period</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,772</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,647</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,419</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ceded medical claims payable, end of period</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross medical claims payable, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,774</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,679</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,453</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

Name	View Source	Status
0001156039-19-000007-index-headers.html	Edgar Link	pending
0001156039-19-000007-index.html	Edgar Link	pending
0001156039-19-000007.txt	Edgar Link	pending
0001156039-19-000007-xbrl.zip	Edgar Link	pending
antm-20190331.xml	Edgar Link	completed
antm-20190331.xsd	Edgar Link	pending
antm-20190331_cal.xml	Edgar Link	unprocessable
antm-20190331_def.xml	Edgar Link	unprocessable
antm-20190331_lab.xml	Edgar Link	unprocessable
antm-20190331_pre.xml	Edgar Link	unprocessable
antm-2019331x10q.htm	Edgar Link	pending
exhibit102l-201933110qq120.htm	Edgar Link	pending
exhibit102m-201933110qq120.htm	Edgar Link	pending
exhibit102n-201933110qq120.htm	Edgar Link	pending
exhibit311-201933110qq12019.htm	Edgar Link	pending
exhibit312-201933110qq12019.htm	Edgar Link	pending
exhibit321-201933110qq12019.htm	Edgar Link	pending
exhibit322-201933110qq12019.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ELV
Elevance Health, Inc. Stock $elv

2019 Q1 Form 10-Q Financial Statement

#000115603919000007 Filed on April 24, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELV Elevance Health, Inc. Stock $elv

2019 Q1 Form 10-Q Financial Statement

#000115603919000007 Filed on April 24, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELV
Elevance Health, Inc. Stock $elv